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Summary 
 
 
Glaucoma is a leading cause of visual disability in the UK and major referral reason 
between high street optometry and hospital based ophthalmology. The standard 
optometric tests used to determine necessity of referral are currently leading to a 
high false positive burden on glaucoma clinics. The disease of glaucoma is 
considered to be multifactorial in the reasons for its onset and progression. An 
increasing body of research proposes a vascular dysregulation hypothesis, and 
retinal artery diameter reduction, as a recognisable risk factor for both the onset and 
progression of glaucoma. The Heidelberg Retina Tomograph (HRT) is a 
commercially available laser scanning ophthalmoscope designed principally for the 
detection of glaucoma by evaluation of the optic disc neuroretinal rim. An additional 
ability of the HRT is to measure, via an interactive window, the blood vessels of the 
scanned image without the need for export of the image or magnification to view 
them in detail. This thesis contributes to the field of early glaucoma detection by 
measurement of artery diameter via the interactive window on the HRT machine. 
The volunteers were divided into three groups normal, glaucoma and ocular 
hypertensive (OHT) and followed over a period of one year to determine if vessel 
diameter changed in relation to visual field or neuroretinal rim parameters. The main 
results in this thesis show that artery diameter does change with glaucoma onset 
and that the HRT machine is a valid instrument for collection of this data. 
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1.0 Introduction 
Glaucoma is an optic neuropathy of unknown origin. Current research has 
suggested vascular factors being involved in the pathogenesis of the disease. One 
of the measurable components of this vascular pathology is blood vessel diameter 
change. The Heidelberg Retinal Tomographer’s (HRT) primary role is detection of 
changes in the neuro-retinal bundle indicating glaucoma onset, or, progression of an 
established disease. The HRT has an interactive tab button that can be used to 
measure diameter of vessels to 0.012mm without the need for additional computer 
software. This research used the HRT to measure the diameter of blood vessels, 
and relate any change in optic disc neuro-retinal rim to glaucoma onset, or, 
progression of established primary open angle glaucoma. Volunteers were divided 
into three groups, normal (n=32, mean age 67), ocular hypertensive (n=27, mean 
age 67) and open angle glaucoma (n=16, mean age 72). Results collected after one 
year (sd 135 days) showed the artery diameter reduced in both glaucoma (RE 
0.009mm t=2.175 p=0.0039, LE 0.01mm t=3.114 p=0.004) and ocular hypertensive 
group (LE 0.001mm t=3.079 p=0.008). These results were consistent with other 
published work and showed the HRT to be a valid instrument for vessel analysis.  
 
1.1 Definition of Glaucoma       
Glaucoma can be defined as “a group of progressive optic neuropathies that have in 
common a slow progressive degeneration of retinal ganglion cells and their axons 
resulting in a distinct appearance of the optic disc and a concomitant visual field 
loss” (Weinreb & Khaw 2004). This definition is not universally accepted and 
variations on the parameters to define glaucoma are normally stated before a 
consideration of any prevalence survey (Foster 2002). 
 
It is a well stated statistic that the prevalence for glaucoma for the over 40 age 
group, in the UK, is 2%(Quigley 1996). In a recent study in Sweden the prevalence 
increased with age, from 0.55% at 55-59 years to 2.73 between 75-79. Of 
significance was the increase of undiagnosed glaucoma with age (Heijl, Bengtsson, 
et al. 2013). To put this in context within the UK population for the same over 40 age 
group, both Diabetes Mellitus and coronary heart disease between the ages of 40-
50 have a prevalence of 2% although this rises significantly with age; Cancer has a 
prevalence of 2% between 50-70 years, chronic obstructive pulmonary disease has 
a prevalence of 2% between the ages of 60-80 years. Diseases within Northern 
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Ireland have a similar distribution, cancer has a prevalence of 2%, chronic 
obstructive pulmonary disorder 1.9% and strokes/transient ischaemic attacks are 
1.8% (Fibrillation 2014). 
 
Intraocular pressure was first described as a significant factor in an optic neuropathy 
causing blindness approximately 100 years ago (Investigators 2000) For many 
years the definition of glaucoma was synonymous with elevated intraocular pressure 
(Hollows & Graham 1966). The study of glaucoma has lead to the discovery of 
progression in eyes where the IOP is well controlled (Öhnell, Heijl, et al. 2016; Spry 
& Johnson 2002) with the increased prevalence of this phenomenon glaucoma is 
now considered a multifactorial disease with inadequate methods of treatment 
(Tielsch 1996). Thus much effort is now directed towards identifying other risk 
factors. 
 
It is difficult to establish causality in the study of glaucoma in humans since one 
cannot isolate a specific trait (Coleman & Miglior 2008). It is also unclear as to 
whether the disease, or the risk factor came first, a problem known as “temporal 
ambiguity”. 
 
The search for risk factors have uncovered a variety of influences on the probability 
of glaucoma onset or progression, some of these are, age (Leske, Heijl, et al. 2007), 
race (Kass 2002), BMI (Leske 1995), central corneal thickness (Brandt, Beiser, et al. 
2004), ischemia (Nickells 1996), vascular dysregulation (Grieshaber, Mozaffarieh, et 
al. 2007), and low ocular perfusion pressure (Leske 2009).  
 
The current treatment of glaucoma is based on reducing the only modifiable risk 
factor namely intraocular pressure, this has been shown to reduce the progression 
of visual field defects attributed to glaucoma (Goldberg 2003).  
 
 
1.2 Epidemiology of Glaucoma 
Epidemiology is the study of causes and spread of a disease within a population.  
 
Worldwide, glaucoma has been estimated to effect 60.5 million people in 2010 
under its two main forms, primary open angle glaucoma (POAG) and primary angle 
closure glaucoma (PACG)(Quigley & Broman 2006). In 2013 this estimate has 
increased to 64.3 million and is projected to continue to rise to 76 million by 2020, 
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118.8 million by 2040 (Tham, Li, et al. 2014). Of the total number diagnosed with 
glaucoma, fourteen per cent will eventually be registered blind. The vast majority of 
this increase will be in Africa and Asia with only a small incremental rise posted in 
Europe, North America and Oceania until 2040.  
 
The Department of Health Social Services and Public Safety in Northern Ireland 
(DHSSPS NI) conducted a sight test survey to gauge overall activity and outcomes 
with optometrists across Northern Ireland (Curran & Dooley 2014). The total referral 
rate was 4.6%, but the percentage within those numbers referred for glaucoma was 
13.3% (table 1). 
 
Referral Category Count % Of all referrals 
Anterior Eye 29 16.1% 
Cataract 42 23.3% 
Contact Lens Service 0 0.0% 
Eye Casualty 1 0.6% 
Glaucoma Service 24 13.3% 
GP 9 5.0% 
Laser 2 1.1% 
Low Vision Service 2 1.1% 
Neurological 3 1.7% 
Orthoptics 6 3.3% 
Paediatric 2 1.1% 
Retinal 36 20.0% 
Visual Loss 12 6.7% 
No Answer Provided 12 6.7% 
TOTAL 180 100.0% 
Table 1 Northern Ireland referral survey 
 
The percentage of patients attending for an eye exam already diagnosed with 
glaucoma was 1.6%, and this would in line with the national average of glaucoma 
prevalence. Of the 180 referrals to ophthalmology 24 patients have been referred to 
the glaucoma service, given a prevalence of 1.6% this would suggest only 3 have 
glaucoma and the others are false positives. 
 
Although it is an accepted statistic that approximately 2% of the population has 
glaucoma, between 50-67% of these patients go undiagnosed (Quigley & Broman 
2006; Burr, Mowatt, et al. 2007). Without detection and treatment glaucoma disease 
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eventually causes blindness. Quigley et al estimated the disease progression by 
extrapolating the data of two random controlled trials for glaucoma progression and 
estimated the time, without intervention, to progress to blindness. For a single eye it 
was 23 years, but with treatment this was extended to 35 years. 
 
Jay et al in 1993 looked at the estimated the mean rate of visual field loss by 
comparing the mean age of presentation of patients with early relative field loss with 
those who presented with absolute field loss within five degrees of fixation at the 
Glasgow infirmary (Jay & Murdoch 1993). Analysis of 177 patients showed similar 
prognosis to reach blindness with treatment to Quigley of 38 years, the rest were 
divided into groups depending on level of presenting IOP. Those with IOP 25-
30mmHg progression to blindness was 6.5 years, whereas below 25 it was 14.4 
years but IOP above 30mmHg blindness was predicted in 2.9 years.  
 
The immediate conclusion for Optometry is that with the UK population at 63.6 
million, and the workforce survey of optometry 2005/6 estimating that there were 
17.5 million examinations per year (Sight Test and Workforce Survey), many cases 
of glaucoma are likely to go undetected. 
 
1.3 Systemic Associations of Glaucoma 
In a study of 180 patients with primary open angle glaucoma the most prevalent 
concomitant disease was systemic hypertension (Salim & Shields 2010) with a total 
of 73% of patients, the next highest was hypercholesterolemia with a significant, but, 
much reduced 47%. The question has to be asked if these conditions are linked or 
is the comorbidity factor simply one of age and therefore of no early consequence in 
diagnosis? 
 
There is also a suggested relationship between glaucoma and neurodegenerative 
diseases such as Alzheimer’s, Alzheimer’s disease being the most common form of 
dementia. The classic findings are personality changes, progressive cognitive 
dysfunction, and loss of ability to perform everyday tasks. Visual impairment is 
common and appears relative to disease severity. Although there appears to be a 
greater percentage of Alzheimer’s patients who have a comorbidity of glaucoma, the 
question is one of whether this is a causal relationship (Wostyn, Audenaert, et al. 
2009). The suggestion by Wostyn (2009) was that, it is known that cerebrospinal 
fluid pressure is lower in dementia patients, and glaucoma patients, therefore, this 
lower pressure made the difference either side of the lamina cribrosa and leave the 
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retinal ganglion cells more susceptible to damage. This hypothesis was refuted in 
2010 by case records (Phillips 2010) where cerebrospinal flow had been operated 
on and the optic discs did not develop cupping as expected. A longitudinal analysis 
over 24 years investigating if primary open angle glaucoma was associated with 
increased risk of developing Alzheimer’s disease concluded no increase risk 
(Kessing, Lopez, et al. 2007). A recent study using a cohort of 87,658 patients 
diagnosed with primary open angle glaucoma, 217,302 with vascular dementia and 
251,703 with Alzheimer’s disease compared to a reference cohort of >2.5 million, 
concluded that the risk of Alzheimer’s following diagnosis of primary open angle 
glaucoma, was not elevated, and the risk for vascular dementia was only modestly 
raised (Keenan, Goldacre, et al. 2015). 
 
Diabetes is very often mentioned as a risk factor in glaucoma but the research is 
split on any correlation. Recent research by Coudrillier et al (Coudrillier, Pijanka, et 
al. 2015) suggested the link was scleral stiffness with diabetic eyes demonstrating 
an accelerated scleral stiffness compared to age matched controls. The age related 
increase in scleral stiffness was 87% larger in diabetic specimens compared to non-
diabetic controls (p=0.06), the study suggested the age related increase in scleral 
stiffness was accelerated in eyes with diabetes which may have important 
implications for glaucoma. A recent meta analysis has suggested a definite link with 
diabetes, diabetes duration and fasting glucose levels being a significant increased 
risk factor for glaucoma, and additionally diabetes and fasting glucose levels being 
associated with slightly higher levels of IOP although this was a much weaker 
correlation (Zhao, Cho, et al. 2015). The suggested reason for the connection was 
vascular perfusion and reduced oxygen levels effecting vascular autoregulation. It 
should also be considered that diabetic patients have eye examination more 
frequently than the normal population so with this increased professional evaluation 
it is likely that glaucoma will be detected earlier. 
 
 
 
1.4  Impact of Glaucoma on Everyday Life 
Glaucoma in its final stage causes blindness. The World Health Organisation 
(WHO) definition of the health related quality of life (HRQoL) involves specific 
activities such as mobility, reading and driving. An additional aspect is psychosocial 
functioning, which is described as the psychological, social and emotional burdens 
of glaucoma. These aspects represent a growing interest from WHO and are 
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recognised as a distinctly different burden than ability to perform vision related 
tasks, but instead is a clinical consequence of chronic medical illness. 
 
In an interesting piece of research by Chan (Chan, Chiang, et al. 2015) considered 
the psychosocial aspects of deteriorating field and acuity. Of the 192 glaucoma 
participants all acuity in the better eye was averaging at 6/9. This is good vision and 
would normally be ignored in the standard glaucoma clinic as a factor effecting 
practical life i.e. HRQoL. But, what the researchers found was that the chronic 
nature of the condition increased their anxiety by 63%, they also exhibited a 71% 
lower self-image and general reduced psychological well being (38%). Although 
there may be very little an eye care provider can do in the limited time spent 
examining a patient for glaucoma deterioration and medication compliance, it is 
worth noting that the patients psychological robustness is not as resilient as one 
might expect given the patients good vision, IOP under control and only mildly 
deteriorated fields. 
 
The majority of patients diagnosed with glaucoma are not registered blind, but, in 
the UK glaucoma is the third largest cause for blindness registration (Green, Siddall, 
et al. 2002). 
 
1.5 Glaucoma Referral from Optometric Practice 
Optometry, with its presence on the high street, ease of immediate access, and 
general availability of diagnostic equipment create an optimum position for early 
detection of glaucoma with obvious benefits for the public. The benefits for individual 
patients could be described as 
• Appointment availability 
• Ease of premises access 
• Diagnostic equipment 
• Immediacy of appointments 
 
The difficulty for optometrists is that only two in every hundred patients have 
glaucoma, so, the habit of seeing normal people makes the abnormal easy to 
detect, but, glaucoma in its infancy masquerades as normal.  
 
Optometrists are responsible for 90% of glaucoma referrals in the UK and patients 
with primary open angle glaucoma contribute 25% of the workload in the hospital 
eye service (Gilchrist 2000). Unfortunately the other headline figure is that 
  9 
undetected glaucoma cases in the community are estimated to be between 50-67% 
(Quigley 1996; Weih 2001; Burr, Mowatt, et al. 2007). A survey of the outcomes of 
referrals by UK community optometrist over a ten year period showed only 18% as 
positive referrals and 45.8% discharged at first review (Bowling, Chen, et al. 2005).  
 
For Optometry this leads to a dichotomy of statistics suggesting on one hand a 
majority stake hold in referral to glaucoma clinics, but yielding high false positive 
rate, and therefore excessive use of ophthalmology resources. The clinical 
effectiveness an cost-effectiveness of screening for open angle glaucoma was 
assessed in the UK 2007 (Burr, Mowatt, et al. 2007).  They assumed that with 
treatment the time to blindness in at least one eye was 23 years but with treatment 
this was extended to 35 years. Their statistics suggest that general screening of the 
population at any age is not cost-effective. Selecting groups with a higher 
prevalence of glaucoma e.g. family history, black ethnicity did appear to be 
worthwhile but this only included 6% of the population. Extending the groups further 
to cover other at-risk cohorts e.g. myopia reduced the prevalence and again was not 
cost effective. The economic model proposed has considerable parameter 
uncertainties and should either the cost of visual impairment rise or the rate of 
progression of glaucoma increase then the statistics for cost-effectiveness for 
screening become more favourable.  
 
For the high street optometrist there is a pressure not to miss any pathology, set 
against an almost zero negative outcome for a high false positive referral rate. 
There is no disincentive to ‘not’ refer, and from a business reputation perspective 
there is a pressure to err on the side of caution. 
 
A survey of optometry practices in N.Ireland assessed their readiness to take part in 
glaucoma co-management (Willis, Rankin, et al. 2000). The conclusion was that the 
equipment needed, namely tonometer, visual field instrument and some method of 
disc evaluation were present, but that more training was needed to effectively 
monitor an active condition. A UK wide survey of equipment found that most 
optometrists were well equipped for glaucoma detection but that the type of 
machines used was varied (Myint, Edgar, et al. 2011). The real problem is not the 
machines being used but the optometric knowledge applied to the patient and 
interpretation of results. An insightful comparison of survey results and actual 
patient experience was carried out in 2012 and found a poor correlation between 
self-reported clinical tests and routine tests performed on actual patients 
(Theodossiades, Myint, et al. 2012). This suggestion of below acceptable standard, 
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despite the high standard of equipment available, becomes manifest when referring, 
and the requirement to put medical diagnosis on paper. A survey of optometry 
referrals concluded that only 49% were of acceptable quality (Scully, Chu, et al. 
2009). 
 
The temptation is that one type of instrumentation becomes a panacea for glaucoma 
diagnosis, but as research has shown (Ng, Zangwill, et al. 2006) agreement 
between the visual field and the optic nerve head imaged by the HRT over a three 
month time period was only fair. The suggestion is that structural and functional 
tests are complimentary, and should be used in combination, for early detection of 
glaucoma. The only feasible way to improve glaucoma detection and referral is to 
raise the knowledge level of high street optometrists.  
 
If it was shown that artery/vein diameter reduction was consistent in prediction of 
glaucoma diagnosis, then this could become a simple fourth measurement to 
reduce false positive referrals to the hospital system. It would only be with 
considerable further research that the weighting factor of this change could be 
compared to the known changes in IOP, disc changes and visual field loss. 
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2.0 Materials and Methods 
2.1 Optic Nerve Head Anatomy 
There are several parameters used to describe the optic nerve head (ONH) 
• Size and shape of disc 
• Size and shape of neuroretinal rim 
• Size, shape and depth of optic cup in relation to size of disc 
• Position of blood vessels in relation to neuroretinal rim 
• Presence and position of peripapillary atrophy 
 
There is considerable variability between individuals in a normal optic nerve. The 
ONH can vary in area from 0.8mm2 to 5.6mm2, with the average for Caucasians 
being in the range 1.74mm2 to 2.47mm2 and neuroretinal rim area ranging from 
0.8mm2to 4.66mm2 (Jonas, Gusek, et al. 1988; Hoffmann, Zangwill, et al. 2007). It 
was also noted in this study that the horizontal cup/disc ratio was larger in 93.2% 
discs compared to vertical, thereby describing a vertically oval optic disc with a 
horizontally oval optic cup. The optic disc size does not vary significantly between 
males and females (Zangwill, Weinreb, et al. 2004) and the disc ceases to grow 
around the age 3-10 years old (Garway-Heath, Rudnicka, et al. 1998). 
The degree of refractive error is correlated with disc size and is significantly smaller 
in eyes with a refraction of >+5.00 dioptres and larger in eyes >-8.00 dioptres 
compared to emmetropic eyes. However between the range +5.00>-5.00 optic disc 
size does not correlate with refraction (Jonas, Gusek, et al. 1988). 
 
Although not applicable to the ethnic groups evaluated in this research, black 
individuals have significantly larger disc area compared to Caucasians and this must 
be taken into account when assessing the neuroretinal rim volume for glaucoma. 
The disc size smallest to largest appears to follow the trend Caucasian, Mexican, 
Asian and largest African-American The known increase in prevalence amongst 
African American is thought to be due to other comorbidities such as genetic 
susceptibility (Hoffmann, Zangwill, et al. 2007). The size of the disc is not effected 
by glaucoma (Caprioli 1992). 
 
The optic nerve is the weak spot in an otherwise strong corneal-scleral envelope. 
The lamina cribrosa provides structural and functional support of the retinal ganglion 
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cells as they exit the relatively high-pressure ocular environment and enter the 
relatively low-pressure region in the retrobulbar space. The lamina cribrosa has 
developed into a complex structure to support the retinal ganglion cells and is 
nourished by the short posterior ciliary arteries. (Figure 1) 
 
 
Figure 1 Vascular supply Optic Nerve Head 
(https://classconnection.s3.amazonaws.com/68/flashcards/1756068/png/screen_sh
ot_2013-02-08_at_121258_am1360300399719.png) 
 
2.2  Ageing Changes 
Death of the retinal ganglion cells and its associated loss of neuroretinal tissue 
observed at the optic nerve head is the hallmark of glaucomatous damage. There is 
considerable variation in the total number of retinal ganglion cells in the normal eye. 
The count varies between 600,000 - 1.2 million between different reports (Medeiros, 
Zangwill, et al. 2012; Medeiros, Lisboa, et al. 2013; Mikelberg, Drance, et al. 1989). 
Additional normal variability is found in the reduction of ganglion cell density with 
age (Repka & Quigley 1989), and this loss may accelerate after middle age (Jonas, 
Schmidt, et al. 1992). Jonas estimated that there was a mean loss of 4000 fibres 
annually after the age of 40 and this loss had the appearance of a bulk reduction in 
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volume rather than focal notching typical of glaucoma. Ageing also leads to a loss of 
retinal cells at an average rate of 0.3% across retinal photoreceptors (Panda-Jonas, 
Jonas, et al. 1995), retinal pigment epithelial cells (Panda-Jonas, Jonas, et al. 1995) 
and retinal ganglion cell axons (Repka & Quigley 1989).  
 
2.3  Glaucomatous Changes 
Loss of neuroretinal rim tissue with enlargement of the optic cup is the hallmark of 
glaucoma. This characteristic cupping of the optic nerve head is due to a 
combination of posterior bowing of the lamina cribrosa and apoptosis of retinal 
ganglion cells (RGC)(Xu, Weinreb, et al. 2014). The neuroretinal rim volume is 
affected in all quadrants but each sector involvement may be differentially effected 
depending on the stage of the disease (Jonas, Budde, et al. 1999). This pattern of 
change is not found in other causes of RGC death. 
 
The pattern of glaucoma neuroretinal rim loss appears to start in the inferotemporal 
disc region and then progress to superotemporal, temporal horizontal, inferior nasal 
and finally superior nasal (Jonas, Fernández, et al. 1993). 
 
A well-documented clinical feature of glaucoma is an optic disc haemorrhage (Suh & 
Park 2014). Disc haemorrhage is more commonly detected in open angle glaucoma 
with normal tension than in open angle glaucoma with high tension. The prevalence 
of disc haemorrhage in normal tension glaucoma is between 20.5% and 33.3%, but 
in high-tension glaucoma only between 8.3% and 17.6%. The prevalence of disc 
haemorrhage was found to be independent of gender (Suh & Park 2011). 
 
Figure 2 Four pressures known to impact on optic disc (Berdahl, Allingham et al 2008) 
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There are four pressures that are thought to interact and effect glaucoma 
progression (Figure 2) Cerebrospinal fluid (CSF) surrounding the optic nerve is a 
balance between the anterior force of the CSF pressure and the posterior force of 
the IOP in the area of the optic disc called the lamina cribrosa. The concern is that 
variations in this pressure difference can damage the optic disc (Berdahl, Allingham, 
et al. 2008). Blood pressure is linked with glaucoma in the form of ocular perfusion 
pressure (Costa, Arcieri, et al. 2009). This is a mathematical equation, which takes 
into account diastolic blood pressure and systolic blood pressure alongside IOP. It is 
considered in more detail in section 2.8. 
 
2.4 Measurement of Blood Vessels 
The first reference to using the HRT as a method of measuring blood vessel 
diameters was in 1997 (Joos, Singleton, et al. 1997), the scan from the HRT was 
uploaded to PhotoshopTM software to improve the image quality and the 
measurement of vessels diameters compared between the two results. The HRT 
was found to be capable of measuring diameters although doubt was cast on the 
ability to detect vessel edges without photo enhancement. 
 
The parameters of blood vessel change in diameter must be consistent across all 
refractive errors in a named ethnicity. Heidelberg has considered this potential 
liability when calculating for neurofibre rim volume. The HRT makes key 
assumptions about the eye involving refractive index of aqueous and vitreous 
humour and equivalent power of the cornea. These assumptions are then modified 
with the known value of the C-Curve (mm), which is the average value of the K 
readings. 
(EQ1) C-Curve = (horizontal + vertical K-reading)/2 
 
The keratometer readings were entered for every patient before scans were taken 
so that accuracy of measurements was maximised. 
 
This approximation of eye parameters can be made more accurate by the 
measurement of axial length but the difference when this extra measurement was 
used in calculation compared to the HRT method was found to be insignificant 
(Garway-Heath, Rudnicka, et al. 1998). 
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The measurements for this research were carried out according to previously 
established procedures (Knudtson, Lee, et al. 2003), explained below.  
 
Figure 3 Zone A and Zone B placement for measurement of vessel diameter (Knudtson et al) 
 
Zone A is one half disc diameter from the optic disc margin and zone B is between 
half disc diameter and one and one half disc diameter from optic disc margin. All 
retinal vessel measurements were taken in zone B (Figure 3). 
 
The vertical length of the optic disc was measured by using the interactive 
measurements tab of the HRT 3 (version 1.5.10.0, 2006 Heidelberg Engineering 
GmbH). The horizontal line was placed at perpendicular to the edge of the 
neuroretinal rim and the y-axis number noted, the horizontal line was then moved 
down to the inferior edge of the neuroretinal rim and the vertical height calculated as 
the top number subtracting the bottom. Half of this vertical height was then added to 
the top and bottom of the disc edges to give the start of zone B. The edge of zone B 
was simply this edge plus half of the disc height. 
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Figure 4 Measurements taken of BV diameter above and below on blue horizontal lines 
 
The position of the horizontal line within zone B was determined as a best-fit line to 
cross as many vessels perpendicular to their direction as possible. Any vessels 
travelling parallel to the horizontal line in zone B were ignored, in some cases the 
defined measurement line would travel obliquely across a blood vessel. This oblique 
diameter would on many occasions be larger than the average diameter of either 
arteries or veins, but, the yearly follow-up measurement is taken along the exact 
horizontal line and it is the change in diameter that is correlated with glaucoma 
onset or progression. 
 
The diameter of the blood vessel is the distance between vessel edges as crossed 
by the best-fit horizontal line. The HRT is able to measure to 0.001mm axially so in 
theory there was no minimum vessels diameter. An important practical, restricting 
parameter, was that the cursor only allowed movements of 0.011mm between two 
positions. Vessels that overlapped obscuring vessel edges could not be included, 
but these crossing were minimised by best-fit horizontal line. 
 
The horizontal y-axis value was noted and used for the comparative measurements 
for that particular volunteer one-year later. Because the HRT aligned the second 
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visit scan to the same orientation as the first all blood vessels were at the same 
angle to the designated line and therefore all measurements were comparable. 
 
2.5 Visual Field Measurement 
Visual field for this research was performed exclusively on the Humphrey Visual 
Field Analyser (Carl Zeiss Meditech, Dublin, CA). The values used in comparative 
statistics were the mean deviation and pattern standard deviation values calculated 
by the Humphrey Statpac program. The visual field is classed as unreliable if the 
numbers of fixation losses exceed 33%. This is a figure that has been raised from 
the original accepted cut off point of 20%. The lower point was calculated by 
Sanabria et al (Sanabria, Feuer, et al. 1991), who had found that the sensitivity and 
specificity dropped off past this percentage of fixation losses. The accepted fixation 
loss percentage has since been raised to 33% because of research done that 
showed diagnosed glaucoma patients missed more points because the disease had 
a reduced field sensitivity and therefore made patient fixation less reliable (Katz, 
Gilbert, et al. 1997). In order to combat this inherent unreliability the number of field 
tests within two years has been raised to a recommend five so as to determine a 
reliable mean field defect (Artes & Chauhan 2005). The stimulus size for this 
research is the accepted value of Goldmann size III, this size was chosen because it 
has been shown to be more resistant to optical defocus (Atchison 1987), and lens 
opacities (Wood, Wild, et al. 1987). 
 
2.6 Vessel Analyses 
 
There have been two methods used in literature for summarising retinal vein 
measurements taken from digitised or digital retinal images; 
 
1/ Methods for Evaluation of Retinal Micro vascular Abnormalities Associated with 
Hypertension/Sclerosis in the Arthrosclerosis Risk in Communities Study (Hubbard, 
Brothers, et al. 1999) 
 
2/ Revised Formulas for summarising retinal vessel diameters (Knudtson, Lee, et al. 
2003) 
 
The Parr-Hubbard method was a combination of the methods developed by Parr et 
al and Hubbard et al (Parr & Spears 1974)(Hubbard, Brothers, et al. 1999) the 
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original Parr method attributed a different multiplication factor to each vein or artery 
depending on is level of branching from the main trunk. This is a very labour 
intensive exercise and is prone to errors because disc resolution did not always 
allow an exact determination of branching. The revised formula of Parr-Hubbard just 
combined the largest vessel with the smallest and disregarded branching continuing 
pairing and calculation until a central equivalent value was obtained.  
 
This research will use the most common formula used in current literature, “Revised 
Formulas for summarising retinal vessel diameters”. 
 
The revised formula is restricted to the six largest retinal arterioles and veins 
(Knudtson, Lee, et al. 2003). To compensate for the considerable variation in the 
number of bifurcations in an eye the relationship between trunks and branches was 
expressed in terms of an empirically derived branching coefficient. 
 
(EQ2) Branching Coefficient = (w21 + w22)/W2 
 
Where w1, w2 and W are the widths of narrow branch, the wider branch and the 
parent trunk. The branching coefficient was estimated by Knudtson et al to be 1.28 
for arteries and 1.11 for veins. When inserted into the above formula and solved for 
W it yields two approximate formals for vessel equivalents 
 
(EQ3) Arteries W= 0.88*(w21 + w22)1/2 
 
(EQ4) Venules W= 0.95*(w21 + w22)1/2 
 
These formulas provide a more precise and consistent estimate of retinal vessel 
calibre and so these were chosen to calculate central retinal artery equivalent 
(CRAE) and central retinal vein equivalent (CRVE) for this research. 
 
The mean of the arteries RE and LE were calculated. This value allowed 
comparison to past and current research measurements to assess if they were 
generally in agreement (Table 2). 
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 Arterial Diameter RE (μm) 
Blue Mountains Study (2005) Present Study Beaver Eye 
Dam (2004) 
RE RE RE 
Normal 194.0 (0.4) 301.5 (41.5) 202.3 (21.97) 
Glaucoma 183.0 (2.6) 262.2 (20.47) ----- 
OHT 195.0 (1.6) 271.9 (29.6) ----- 
Table 2 Comparison of Current Research Artery Diameters RE with Present Research 
 
The larger diameter measurement taken with the HRT interactive tab is explained by 
the axis of the dissecting line of the artery or vein. The horizontal line is fixed at a 
certain y-value; this allows continuity of position for measuring future vessel 
diameters. The line intercepts the arteries and veins at different angles, which are 
greater than a perpendicular bisect of the vein, increasing the measured diameter. 
The important measurement is not the measured diameter compared against a 
normative set of data, but instead the difference between two consecutive 
diameters, measured at the same position, one year apart. Although the average 
diameter does not correspond with the research normal it is the change of diameter, 
which is the important consideration and the results from this research do follow the 
accepted at risk groups. The larger value of the standard deviation is explained by 
the bisection of some blood vessels being perpendicular and others being closer to 
parallel. 
 
The arteries and veins were measured and the average diameter at baseline and 
one year is shown (table 3&4) 
 
 
 R&L arterial mean baseline and one year 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal 301.5 (41.5) 269.9 (60.97) 302.4 (38.6) 269.2 (59.38) 
Glaucoma 262.2 (20.47) 246.3 (38.53) 257.8 (23.4) 236.6 (38.04) 
OHT 271.9 (29.6) 260.0 (48.69) 262.8 (34.83) 249.6 (37.07) 
Table 3 R&L arterial mean baseline and one year 
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 R&L Venous mean baseline and one year 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal 349.3 (45.29) 329.7 (72.71) 344.4 (41.39) 332.4 (72.56) 
Glaucoma 315.8 (46.66) 285.4 (34.13) 310.0 (39.36) 282.7 (28.36) 
OHT 344.2 (40.49) 326.8 (37.18) 330.3 (37.45) 322.4 (32.67) 
Table 4 R&L Venous Mean baseline and one year 
 
In the normal group using a paired sample t-test there was no significant difference 
between either the RE mean artery diameter baseline and one year (t=-0.322, 
df=31, p=0.75) or LE (t=0.210, df=31, t=0.84). There was a significant change in 
diameter in the Hypertensive group for both the RE (t=2.175, df=26, t=0.039) and LE 
(t=3.11, df=26, t=0.04). The final glaucoma group did not show a difference from 
baseline with the RE (t=1.083, df=15, p=0.296) but there was a significant change 
for the LE (t=3.079, df=15, t=0.08), (figure 5+6). 
 
 
Figure 5 RE Mean Artery Baseline and One Year 
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Figure 6 LE Mean Artery Baseline and One Year 
Comparing the vein diameter change there was no significant difference in either the 
normal or glaucoma group, but, the Hypertensive group had a significant change in 
the RE (t=3.237, df=26, t=0.03) but not the LE (t=1.254, df=26, t=0.221). 
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2.7 Ocular Blood Supply 
 
Figure 7 Anatomy of Ocular Blood Supply (http://www.retinareference.com/anatomy/arterial.jpg) 
The common carotid artery provides circulation to the head and neck; this major 
artery divides into two, called the internal and external carotid. It is the internal 
carotid that subdivides into the ophthalmic artery and subsequently the central 
retinal artery and posterior ciliary arteries (figure 7). There is considerable variation 
in the exact pattern of branching from the ophthalmic artery, but, the central retinal 
artery is one of the first, and smallest of the branches leaving the main ophthalmic 
artery as it lies below the optic nerve and enters the sheath of the nerve about 10-12 
mm behind the globe (Remington 2011). Within the optic nerve, collaterals come off 
the central retinal artery to supply the nerve itself, and pia mater. The central retinal 
artery passes through the lamina cribrosa approximately 8mm posterior to the globe 
and travels anteriorly central in the optic nerve until it enters the optic disc and 
divides into superior, inferior, nasal and temporal branches (Semmer, McLoon, et al. 
2010; Bell, Severson, et al. 2009)(figure 8). 
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Figure 8 Blood Supply to the Optic Nerve Head  
(http://clinicalgate.com/wp-content/uploads/2015/04/B9781437704341000153_f015-
003-97814377043413.jpg) 
The posterior ciliary artery (PCA) circulation is the major source of blood supply to 
the ocular structures and optic nerve head. After branching from the ophthalmic 
artery they travel along the optic nerve and further divide into multiple branches, 
which then pierce the sclera around the optic disc. The PCAs are the blood supply 
for the optic nerve head, peripapillary choroid circle of Zinn, Haller and choroid. 
These choriocapillaries exist as a single network of continuous capillaries located 
directly beneath the retinal pigment epithelium. This choroidal circulation accounts 
for 85% of the total ocular blood flow (Ehrlich, Harris, et al. 2010). 
 
The major source of blood supply to the inner retina (extending from neuroretinal 
layer to inner nuclear layer) is the central retinal vein. The outer portion of the retina 
(outer section of inner nuclear layer to retinal pigment epithelium) receives its blood 
supply from the choriocapillaries. 
 
Retinal circulation is characterised by a low level of flow and high level of oxygen 
extraction. It is autoregulated, but receives no autonomic innervation. Tight junctions 
exist between the capillary endothelial cells forming a blood retinal barrier similar to 
the blood brain barrier of the CNS (Hofman, Hoyng, et al. 2001). This barrier 
protects the tissues by only allowing metabolites through, but, the optic nerve head 
prelaminar portion has been shown to be not as efficient a barrier as the rest of the 
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retinal circulation and this may have some part to play in allowing a damaging 
permeability and effect regulation of blood flow (Hofman, Hoyng, et al. 2001). 
 
2.7.1 Changes in a Normal Eye 
The definition of a normal blood vessel diameter is difficult given the number of 
confounding factors namely, age (García-Ortiz, Recio-Rodríguez, et al. 2015), sex, 
ethnicity, optic disc size (Lee, Klein, et al. 2007), and systemic conditions (Sun, 
Wang, et al. 2009; Sherry, Wang, et al. 2002; Leung, Wang, et al. 2003). Older 
people are known to possess a narrower vascular calibre. Retinal arterioles are 
estimated to decrease by 1.8-4.8μm for each decade of increasing age independent 
of sex and hypertension (Leung, Wang, et al. 2003; Wong, Klein, et al. 2003). 
Retinal blood vessels are an everyday observation for the high street optometrist. 
The vessels are described on patient record cards in terms of tortuosity, artery/vein 
(A/V) ratio and any focal decrease of the vein diameter crossed over by an artery. 
 
The historical reason for assessing blood vessel calibre is to predict the possibility of 
systemic blood pressure and refer for treatment. The prevalence of blood pressure 
over the age of 40 in the UK (taken at >160/90) is 10-15% of the population (Sharp, 
Chaturvedi, et al. 1995). The patients with systemic hypertension have an increased 
mortality rate compared to normotensive from stroke (Ikram, De Jong, et al. 2006), 
coronary artery disease (Wong, Kamineni, et al. 2006), and peripheral arterial 
disease (Rosendorff, Lackland, et al. 2015). It is with this background of blood 
pressure detection in the eye that all optometrists are trained to observe retinal 
vessel calibre. 
 
The commonly quoted A/V ratio is used to describe artery narrowing as a 
comparison to vein diameter. Arteriolar narrowing is associated with prolonged 
raised blood pressure, particularly diastolic (Scheie 1953), and age (Fuchs, Maestri, 
et al. 1995). The other features used to describe artery changes linked with blood 
pressure are arteriolar reflex, arteriolar tortuosity and focal arteriolar calibre changes 
(Hurcomb, Wolffsohn, et al. 2001). It has been estimated that with each 10mmHg 
increase in arterial blood pressure the retinal arterioles reduced by 2.0-2.4μm 
(Mitchell, Cheung, et al. 2007). Unfortunately subtle changes of A/V ratio are difficult 
to reproduce in manual assessment, and consistency is variable with practitioners of 
different education and experience (Heitmar, Kalitzeos, et al. 2015). 
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Medication may also be a complicating factor in the clinical decision as to whether 
blood vessel diameter has changed due to glaucoma. The question of vessel 
diameter change due to systemic medication has been considered (Wong, 
Knudtson, et al. 2005), the retinal photographs in the Beaver Dam Eye Study were 
digitised and retinal vessels measured and compared to the participants current 
medication. There were no significant correlations other than patients already taking 
beta-blocker topical medication had narrower arterial and venous diameters, but 
notably those taking beta-blocker systemic medication did not. 
 
Although this research did not include multi-ethnicity participants, measurement 
across a range of ethnic background reveals that black and Hispanic individuals 
have larger arteriolar and venular calibres than whites and Chinese (Tien, Islam, et 
al. 2006). Of greater significance was the association of smaller retinal arteries to 
higher diastolic and systolic blood pressure, current alcohol consumption, greater 
body mass index and higher levels of homocysteine. Larger retinal arteries were 
related to diabetes, current cigarette smoking and higher levels of plasma 
fibrinogen. Larger retinal veins were related to diabetes, current cigarette smoking, 
greater body mass index and higher levels of serum glucose. 
 
Retinal vascular calibre is gathering an increased background of research to 
indicate validity in its measurement as a routine part of medical data collection as a 
prognostic factor for a patient without signs or symptoms of any ocular condition. 
The Blue Mountains Eye Study examined 3654 patients at baseline and 2461 
patients at 5 and 10 years and concluded that retinal arteriolar narrowing was 
associated with long term risk of open angle glaucoma (Kawasaki, Wang, et al. 
2013). The difficulty in determining change in blood vessel diameter is not in 
achieving a measurement of that change but in considering how normal the degree 
of change is when set alongside the range of other factors adding to vessel 
narrowing. 
 
 
2.7.2  Retinal Vessel Measurement 
Because vascular calibre is considered a valuable measurement for prediction of 
both cardiovascular and cerebrovascular disease (Sun, Wang, et al. 2009), and the 
retina facilitates non-invasive in vivo measurement of blood vessel diameter, the 
potential prognostic ability to be gained from accurate and repeatable measurement 
of artery and vein diameters has lead to a number of instruments being developed 
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to attain data, Fundus photography, Zeiss Retinal Vessel Analyser and the Dynamic 
Vessel Analyser. 
 
Fundus photography is a standard machine in most high street optometrists. The 
evaluation of blood vessel diameter using these photos is based on the 
development of appropriate software, recent advances have shown good agreement 
with manual measurement (Bhuiyan, Kawasaki, et al. 2013). 
 
The Zeiss Retinal Vessel Analysertm (RVA, Imedos GmbH) is a commercially 
available tool for assessment of retinal vessel diameter in relation to time. The RVA 
assesses retinal vessel diameter by using the brightness difference between blood 
vessels and surrounding retina to allow computer based software to make the 
calculation. Dilation is essential to achieve adequate image quality and a green filter 
is used to attain optimum contrast of the erythrocyte column flowing through the 
blood vessel against the surrounding retina (Garhofer, Bek, et al. 2010). The RVA 
can measure to 90µm. The limitations of the RVA are a requirement for dilation and 
a notable susceptibility to cloudy media e.g. cataract which degrades the image 
making computer analysis of image unreliable. The HRT can compensate for mild 
eye movement but the RVA needs good fixation to achieve quality image. In current 
research with this machine it appears to be an accurate system for measurement of 
blood vessels (Polak 2000). 
 
The Dynamic Vessel Analyser is a commercially available tool for the assessment of 
retinal vessel diameter in relation to time. In principle it analyses the brightness 
profile of the vessel using video sequences obtained with a conventional camera. 
This machine allows stimulation of the blood vessels during image acquisition and 
may in the future be a better version of static measurement (Heitmar, Blann, et al. 
2010). But this may be a difficult machine to bring to the high street optometrist 
given its very specific purpose. 
 
2.8 Ocular Perfusion Pressure 
Blood Pressure is a constant background factor in both the increased risk of 
developing glaucoma (Charlson, de Moraes, et al. 2014), and a potential indicator 
for glaucoma progression (Costa, Arcieri, et al. 2009). It is a known comorbidity 
variable in relation to glaucoma with increased frequency, in glaucoma patients, of 
migraine (Phelps & Corbett 1985), silent myocardial infarction (Kaiser, Flammer, et 
al. 1993), and cerebrovascular accidents (Feldman, Sweeney, et al. 1969). Blood 
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pressure reduces overnight, but a drop of more the 20% compared to the mean 
daytime arterial pressure has been shown to be an important finding in normal 
tension glaucoma patients who progress in visual field defects compared to patients 
who have a smaller daytime/night-time blood pressure disparity (Lee, Choi, et al. 
2015).  
 
Blood pressure can be converted in combination with IOP, to ocular perfusion 
pressure, and it is this variable, which is a more useful indicator in the detection 
glaucoma, or, it’s prediction for progression. 
 
In this research a battery operated Omron BP monitor was used to attain the blood 
pressure values. This was done via an arm cuff that was wrapped around the 
patient’s bare left arm and the start button pressed on the machine. After inflation 
and deflation the machine produced two readings, diastolic pressure and systolic 
pressure. The systolic pressure is defined as the pressure in the arteries when the 
contraction of the heart forces blood into them at the height of pulsation. The 
diastolic pressure is the pressure maintained by the elastic recoil of the large 
arteries during cardiac relaxation. 
 
The gold standard for BP measurement is the mercury sphygmomanometer. The 
Omron monitor (MIT3 HEM-7270-E, Omron Healthcare Europe B.V.) was chosen, it 
is well known in high street pharmacies. Measuring BP using the arm cuff has well 
documented instructions to reduce erroneous readings generally attributable to poor 
cuff positioning (Ramsey 1991). This type of automated instrument was compared 
to the gold standard and the comparative results were considered valid (Yacoub, 
Dettenborn, et al. 2005).   
 
Ocular perfusion pressure (OPP) is defined as the difference between arterial and 
venous pressure. In the eye, venous pressure is considered to be the same or 
slightly higher than IOP. OPP can therefore be defined as the difference between 
IOP and BP. This can further be broken down into diastolic and systolic perfusion 
pressure. In the eye, the ocular perfusion pressure can be referred to as systolic 
(SOPP), diastolic (DOPP) and mean ocular perfusion pressure (MOPP). MOPP is 
calculated by the formula 
 
(EQ5) Mean Ocular Perfusion Pressure= 2/3 (DBP+1/3(SBP-DBP))-IOP 
DBP= diastolic blood pressure     SBP= systolic blood pressure      IOP=intraocular pressure 
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When recording MOPP over 24 hours two different equations were used for sitting 
and supine body positions. The supine position is calculated by multiplying by 
115/130 and the sitting position uses the multiplier 95/140, this was used as the 
equation to calculate MOPP when the patient was monitored for 24 hours. 
 
Further ocular perfusion pressure equations divide out systolic and diastolic values 
 
(EQ6) Systolic Ocular Perfusion Pressure= Systolic Blood Pressure-IOP 
 
(EQ7) Diastolic Ocular Perfusion Pressure=Diastolic Blood Pressure-IOP 
 
OPP is complex because of auto regulatory processes that attempts to keep blood 
flow constant. Epidemiological studies have shown low OPP to be a risk factor in the 
prevalence, incidence and progression of glaucoma (Leske 2009). The Early 
Manifest Glaucoma Trial (EMGT) reported that patients with low systolic OPP 
showed almost a 50% higher risk for the progression of glaucoma (Leske, Heijl, et 
al. 2007). In contrast, the Rotterdam Eye study (Hulsman, Vingerling, et al. 2007) 
showed an increased risk of progression, with only diastolic ocular perfusion 
pressure. This obvious dichotomy between which perfusion pressure measurement 
is the significant predictor for glaucoma is further complicated by the results from 
Kidd et al (2008), who monitored ocular blood flow using a scanning laser Doppler 
flowmeter. This recorded blood volume, flow and velocity in the sitting position. Their 
results demonstrated that older patients had a reduced ocular blood flow at night 
despite MOPP remaining constant throughout the 24-hour cycle. This was in 
contrast to younger patients who had no change in ocular blood flow despite MOPP 
reducing significantly at night (Kida, Liu, et al. 2008). The conclusion was that age 
compromised the auto regulatory capacity present in younger patients to ensure 
adequate perfusion of ocular tissues. Glaucoma and a normal control group were 
compared for diurnal variation over 24 hours by Sehi et al, they concluded the 
variation was widest for glaucoma and the MOPP value was lowest at 7am, a time 
whenever IOP is reaching its peak and BP measurements are in a trough (Sehi, 
Flanagan, et al. 2005). 
 
The control of the blood pressure, and consequently, ocular perfusion pressure, has 
been shown to reduced visual field progression in those receiving blood pressure 
medication (Hirooka, Baba, et al. 2006). Blood pressure is diurnal, but unlike IOP, it 
has its lowest point around 3am compared to an increasing IOP. This increased dip 
in blood pressure at night has been postulated to be responsible for visual field 
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progression in glaucoma sufferers with otherwise stable IOP (Graham & Drance 
1999; Charlson, de Moraes, et al. 2014). The variation of IOP over 24 hours was 
estimated to be a risk factor for glaucoma if it varied by greater than 9.4mmHg 
(Hughes, Spry, et al. 2003).  
 
The opposite IOP rhythm is difficult to explain since aqueous production is known to 
decrease at night (Reiss, Lee, et al. 1984), it has been postulated that this increase 
in IOP is due to reduced episcleral outflow. 
 
Auto regulation is the ability of the capillary bed to regulate blood flow via resistance 
in the vein. This is necessary to allow a stable environment for the cells in normal 
blood pressure variation. In contrast to the extra ocular and choroidal vessels, 
retinal vessels have no neural innervation, therefore only local vascular mechanisms 
are responsible for regulating flow (Schmidl, Garhofer, et al. 2011). Glaucoma is 
considered to have impaired blood flow regulation, one study comparing resistance 
in the central retinal artery between normal and glaucoma subjects in the sitting and 
supine position showed an inability to adjust resistance in glaucoma patients (Feke 
& Pasquale 2008). Grieshaber et al have alluded to this abnormal auto regulation, in 
the form of vascular dysregulation. They suggested an underlying endothelium 
defect. The vascular endothelium cells are a confluent monolayer of flattened cells 
that line blood vessels. This layer acts to regulate vascular tone and when the 
complex chemical chain breaks down the result is an irregular vasospasm which 
effects ocular blood flow (Grieshaber, Mozaffarieh, et al. 2007). They named this 
phenomenon endothelium based defect primary vascular dysregulation and linked it 
to cold extremities and reduced desire to drink due to reduced reabsorption of salt in 
the kidneys. This link with sodium uptake and normal tension glaucoma has been 
noted before (Pechere-Bertschi, Sunaric-Megevand, et al. 2007). This background 
catalyst for glaucoma leads to the potential assertion of two distinct types of chronic 
open angle glaucoma, type one driven by vasospastic factors and not as easy to 
control with IOP lowering drugs and the other which responds well to reduction of 
IOP (Schulzer, Drance, et al. 1990). 
 
Because of this weakness in glaucoma patients, then, Ocular Perfusion pressure 
when it is low becomes a risk factor for ischemia during changes in mean arterial 
pressure and diurnal spike in IOP. 
 
As a confounding factor, both diurnal variation of BP and IOP are known to be more 
variable in primary open angle glaucoma with increased spikes and more 
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pronounced troughs generally indicating a greater probability of glaucoma 
(Quaranta, Katsanos, et al. 2013). The normal variation is shown in figure 9 & 10 
 
Figure 9 Normal IOP in sitting and supine position (Quaranta, Katsanos et al 2013) 
 
 
Figure 10 Diurnal BP of Systolic and Diastolic Blood Pressure (Quaranta, Katsanos et al 2013) 
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2.9 Imaging the Optic Nerve Head 
Confocal Microscopy was invented by Professor Marvin Minsky in 1955 (Minsky 
1988) . Professor Minsky’s father was an ophthalmologist and Marvin had spent his 
childhood surrounded by optical instruments and lenses. His obsession with 
understanding the brain lead him to consider the basics of how cells connect to one 
another, and since this could not be done with simple staining techniques the pursuit 
of a machine to measure a single point of illumination took him in the direction of 
confocal microscopy. Initially he used zirconium arc as the light source and moved 
the sample in order to scan it, but it was the future invention of laser and the 
modification of scanning mirrors that made the confocal microscope practical in both 
use and production for retail sale. 
 
The HRT machine was developed in the late 1980’s with the first research paper 
written in 1988 describing the measurement of the optic nerve in vivo (Zinser, 
Wijnaendts-van-Resandt, et al. 1988).  
 
2.9.1  The Heidelberg Retinal Tomograph (HRT) 
The Heidelberg Retina Tomograph 3 (HRT 3) is a confocal scanning laser imaging 
system used for the analysis of three-dimensional images of the posterior segment 
of the eye, specifically the optic nerve head. The HRT has a focal adjustment range 
of -12D to +12D spherical (in 1.00D steps), with external magnetic, clip-on lenses, 
allowing correction of astigmatism in the range -6D to +6D (in 1.00DC steps). The 
image acquisition time is between 1-6 seconds with an optical resolution of 
10μm/pixel transversal and 62μm/pixel longitudinal. The size 3D image acquired is 
384*384*64 pixels. 
 
2.9.2 Imaging Principles 
A Confocal Optical System is defined as “ Measurement of light that can only reach 
the photo detector if it is reflected from a narrow area surrounding the set focal 
plane. Light reflected outside of the focal plane is highly suppressed. For this 
reason, a two dimensional confocal image may be regarded as an optical section 
through an examined object at the location of the focal plane.” (HRT2 & HRT3 
Glaucoma Premium User Manual V3.2).  A series of optical images are acquired for 
different positions along the optical axis giving the resultant three-dimensional 
image, this imaging technique is known as Scanning Laser Tomography. 
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Figure 11 Principles of Confocal Scanning showing placement of pinholes in front of the laser 
and detector 
(https://upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Confocalprinciple_in_
English.svg/1280px-Confocalprinciple_in_English.svg.png) 
 
To acquire the optical section images, laser light is focused on the retina and is 
periodically deflected by oscillating mirrors so that a two dimensional section of the 
retina is scanned sequentially (Figure 11). The HRT moves the focal plane from 
anterior to posterior along the optical axis. This is a build up of the 3D image by 
slices. The amount of light reflected at each point of the slice is measured using a 
light sensitive detector. From the distribution of the amount of light along the optical 
axis i.e. perpendicular to sequential scanned plane, the height of the retinal surface 
can be calculated. The end product is a confocal stack of between 16-64 optical 
slices; the number of slices is determined automatically by pre-forming a pre-scan 
which determines the optimum scanning depth for a particular optic nerve head. 
This mathematical data results in a three dimensional x, y, z matrix that can be 
displayed as a topographic map (Figure 12). 
 
The z-profile (fig 12,b) of each point may be presented as a plot of reflectance 
intensity versus scan depth. The peak intensity from the z-profile plot is assumed to 
correspond to the location of the internal limiting membrane that overlies the retina 
and the optic disc 
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Figure 12 Principle of Confocal Scanning Laser Tomography (a) "stack" of images at 
incremental focal depths. Measurements in the z-axis are referred to as axial, and those of the x 
and y axis are named transverse. (b) The set of axial values at a given transverse coordinate (x1, 
y1) and is known as z-profile. (c) The axial location of each z-profile maximal reflectance at 
coordinate (x1, y1) (d) axial locations are mapped to topographic height image (e) confocal 
scanning three-dimensional representation of (d) 
  
 2.9.3 Image Acquisition and Quality 
The instrument uses a diode laser with a wavelength of 670nm. A three-dimensional 
image is generated as a series of sequential scans, each taking 24 milliseconds 
starting above the retinal surface then capturing parallel images at increasing 
depths.  This 24-millisecond scan per section is faster than involuntary eye 
movements since micro-saccades last for approximately 30-50 milliseconds (Poletti 
& Rucci 2015). Each scan is composed of 384x384 pixels scanning a 15 degree 
area of the retina to a depth of 1-4mm, depending on the determination algorithm of 
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the pre-scan for each patient. Each successive scan plane is set to measure 0.0625 
deeper as scans are taken incrementally through the tissue. Thus, if the pre-scan 
determines that a 1mm scan depth is required, 16 image planes will be used, 
whereas if the depth is 4mm then the imaging planes are set to 64.Three sets of 
scans are automatically captured at each acquisition allowing for data redundancy. 
The stack of image sections is then aligned using Heidelberg’s Trutracktm 
technology, which discards any scan outside acceptable quality standards. This 
quality is determined by a standard deviation calculation between the three 
sequential scans on each point this value is then assigned a cut off value of 50, 
above which the scan is deemed unacceptable scan quality. 
 
The quality reduction may be due to blinking, or fixation shift, and faulty scans are 
automatically repeated to ensure three adequate scans are acquired for image 
analysis. 
 
Three single topography images are acquired automatically by the HRT3 and these 
images are averaged to calculate a mean topography. Image resolution algorithms 
within the HRT software align the three images. This has been shown to be 
accurate and reproducible for topographic images of the optic nerve head 
(Chauhan, LeBlanc, et al. 1994). 
 
The lens is positioned close to the eye but not touching the eyelashes, 
approximately 10mm from the cornea. The pupil does not need to be dilated unless 
it is less than 3mm diameter or there is sufficient cataract opacity reducing image 
quality. The most immediate effect on image quality is poor tear quality and the HRT 
scan must be done prior to fluorescein instillation for readings of Goldmann 
tonometer artificial tears can be used as a tear substitute for patients with 
meibomian gland dysfunction, but, this was not a required solution for these 
research participants. 
 
The quality of the HRT image is a key factor in measuring blood vessels to 
0.001mm. Heidelberg recommends this begins with choosing a suitable lens power 
from the magnetic clip on lenses, this is calculated as a best form lens from entering 
the volunteer’s spectacle prescription into the patient details form and the HRT will 
suggest a best spherical lens. The HRT also has a magnetic clip-on astigmatic for 
prescriptions over +/- 1.00DC. The corneal curvature is entered so that 
magnification can be accounted for should the patient undergo any future corneal 
surgery. All volunteers in this research had refractions under +/- 4.00DS and less 
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than -2.00DC, with no history of corneal surgery or diagnosis of corneal dystrophy. 
This minimised any change in magnification effects on any blood vessel 
measurement. The optic disc was then aligned. The optic disc is centred by first 
directing the volunteer to fixate on a green flashing light inside the camera, the laser 
is then centred to enter the pupil, the live image should appear on screen. Any laser 
light falling on the iris should be avoided as this will lead to a crescent shaped 
shadow on the acquired image. The image is more finely tuned using the focusing 
dial; this value is automatically recorded with the scan and on subsequent images if 
this number changes by more than two dioptres, then a warning notice is flashed up. 
In practice we found patients more easily achieve the correct position by getting 
then to follow the fixation white light mounted on a movable stalk. The 
understanding of an instruction to “look at the white light” or “ follow the white light” 
so that the optic disc could be centred, provided clarity of instruction for the patient, 
leading to quicker image acquisition. We viewed and centred the optic disc placing it 
inside a green target ring superimposed on the live video image. 
 
The image bar gave an immediate estimate of quality based on numerical number 
(0-100) and colour with green indicating good, red is poor and yellow if image 
illumination or patient fixation is only adequate (Figure 13). 
 
 
Figure 13 Image Quality bar during HRT image acquisition (image courtesy of Heidelberg) 
  36 
The image quality of a HRT topography scan is measured by a number of criteria. 
This assessment of image attributes allows the interpretation of the HRT scan to be 
repeatable over time. 
 
The first check is the standard deviation in the analysis centre. Heidelberg 
recommends that images with a standard deviation above 40μm be repeated to 
improve quality. Heidelberg goes further to suggest that a standard deviation above 
50μm should be interpreted with caution. This standard deviation is calculated as a 
geographical mean. The normal arithmetic mean is a simple calculation of sum of 
the parts divided by number of entries;  
 The mean 𝜇𝑎 is calculated as follows:  
(EQ8) 𝜇𝑎 = ,  
Whereas the geometric mean is calculated as follows: 
(EQ9)  
The arithmetic mean considers that each value has no impact on the previous or 
following values, but the geometric mean takes into account that each value relates 
to one another. This is a much better mean of the topographic results. 
The quality of the image is summarised in the “Qualitative Image Assessment” 
window. The image quality score gives as assessment of mean standard deviation 
value of the topography. The imaging quality score gives an overall assessment of 
the variety of parameters that directly effect image definition (Figure 14). 
 
Figure 14 Qualitative Image Assessment Window HRT (image courtesy of Heidelberg) 
 
  37 
2.9.4  Interactive Analysis of the Image 
The tab interactive measurements allow the display of the cross sections of the 
topography to perform height (x, y, z) or horizontal measurements (x, y) (figure 15). 
A single mouse click inside the large image superimposes a green coloured 
crosshair on the image. The horizontal and vertical cross sections show height 
variation of the retinal surface along the horizontal and vertical lines of the 
crosshairs respectively. The crosshairs are manually positioned by moving the 
mouse inside the large image, or alternatively, by using the cursor keys (arrow 
keys). The cursor keys move the crosshairs in increments of 0.011mm horizontally 
and vertically. The coordinates of the crosshairs are shown in the bottom right of the 
screen. There are four different coordinate systems within the HRT software. The 
default system, relative and tilted, was used for this research. In this system “the x,y 
plane runs parallel to the retinal surface and the mean height of the z-axis is 
determined by the mean height of the peri-papillary retinal surface” (definition taken 
from “The Essential HRT Primer” Fingeret, Flanagan & Liebmann). 
 
Figure 15 Reflectance Image in interactive window we used for measuring blood vessel 
diameter (image courtesy of Heidelberg) 
The image can be toggled between reflectance (Figure 15) and topographic (Figure 
16). The reflectance image is a false colour image that appears similar to a 
photograph of the optic disc. The image should be clear and evenly illuminated, with 
sharp borders and visible margins of optic disc and retinal vessels. 
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Figure 16 Topographic image in interactive window we used for measuring blood vessel 
diameter (image courtesy of Heidelberg) 
The reflectance image is the result of the summation of the two dimensional 
reflectance images and is presented as a 384 x 384 pixel map illustrating the degree 
of reflectance from regions in the optic disc and peripapillary retina. Lighter areas 
such as the base of the cup are areas of greatest reflectance. This does not equate 
to height measurement and is purely related to overall reflectance of the image. The 
reflectance image is useful in locating and drawing the contour line around the optic 
disc. 
The topographic image in contrast to the reflectance image does relay information 
about contour height of the optic disc and retina. The image is false colour coded, 
but is based on the height measurement matrix constructed from the determination 
of the depth of maximal reflectance in the z-axis at each pixel (figure 8) Pixels that 
appear bright in the topographic image are deeper and darker pixels are elevated. 
Thus, the neuroretinal rim should appear darker than the surrounding retina and the 
base of the cup usually appears the lightest. 
 
2.9.5  Drawing the Contour Line 
The contour line is the outline of the scleral ring of Elschnig (Figure 17). This is 
estimated to be approximately at the optic disc border. The border is drawn by 
placements of a series of points at the external edge of the optic disc and the HRT 
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machine will draw an automatically derived circle. The diameter and contour of the 
circle can be adjusted to match the individual disc. The scleral ring frequently 
appears as a pale band in the reflectance image, the contour line is then placed on 
the inner edge of this ring. The interactive height contour is very useful since the 
scleral ring is displayed as a depression. The contour line is then drawn on the 
maximum height inside of this depression. The contour line, once accepted, is fixed 
throughout the lifetime of scans for that patient. If, in the future it is decided to 
redraw the contour line, then all measurements for neuro retinal rim volume would 
be recalculated. Because of its manual input, the accuracy of mapping the scleral 
ring of Elschnig has been compared to optical coherence tomography (OCT). 
Research has shown there to be a high correlation (r=0.93 to 0.98) between OCT 
and HRT identification of the optic disc margin (Schuman, Wollstein, et al. 2003). 
This has recently been queried by research based on the increased detail available 
to assess optic disc anatomy with the Heidelberg Spectralis OCT. The original 
Bruch’s membrane opening, thought to define the optic cup margin and 
subsequently the neuro retinal volume, has been reassessed using the Spectralis 
OCT (Chauhan & Burgoyne 2013). If proved to be correct, and accepted as the gold 
standard for optic disc assessment, this new value of rim volume would render the 
HRT version out of synch with average neuro retinal rim volume. 
 
 
Figure 17 Anatomical Position of Elschnig's Ring (permission from Heidelberg Images) 
2.9.6  The Standard Reference Plane 
The mean peripapillary retinal surface height is found from topographic height 
values within a peripheral reference ring shown in figure 18 & 19. 
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Figure 18 HRT position of reference plane (permission from Heidelberg images) 
(http://www.oculist.net/downaton502/prof/ebook/duanes/graphics/figures/v3/048a/00
3f.gif) 
The reference plane is calculated by the HRT after the contour line is drawn. This 
plane is parallel to and below the peripapillary retinal surface and is used to divide 
the optic disc into neuroretinal rim and cup (Burk, Vihanninjoki, et al. 2000). 
 
Figure 19 Reference Ring Schematic for HRT (permission Heidelberg images) 
 
The HRT3 has built in software for assessing the normality or an optic disc. This 
software uses an expanded normative database compared to HRT2 and HRT-
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classic. It now includes 733 healthy eyes and 215 healthy African-American eyes 
(HRT glaucoma module operating instructions software version 3.0 Heidelberg 
Engineering). With this normal population the software equations were modified to 
improve accuracy. 
 
In this research the glaucoma software results were not included in the statistics. 
The main focus of this research was to correlate vessel diameter change with 
neurofiber volume loss and visual field defects. The software included with the HRT 
is used to aid diagnosis of glaucoma based on probability of the disease set against 
a normal database or statistically abnormal change typical of glaucoma. 
 
The important results obtained from the HRT were in the stereometric parameters 
tab which were calculated by the HRT after the contour line was drawn and 
reference plane set. 
 
2.9.7  Moorfields Regression Analysis (MRA) 
This algorithm takes a different approach to the normal derivation of software by 
supplying a machine with two sets of data, one normal and one defined as 
glaucoma then allowing the statistics, via linear discrimination, to determine the best 
parameters to distinguish the two groups. Instead, Moorfields Regression Analysis 
(MRA) was born of knowledge ‘ a priori’ i.e. the dependence or neuroretinal rim area 
on disc size, the possibility that neuroretinal rim area may decline with age, and 
knowledge of the glaucomatous process. The results are then presented as a bar 
chart as to whether the individual sectors are within, or outside normal limits. The 
decision as to whether this represents glaucomatous change is left with the clinician. 
 
2.9.8  Global Probability Score (GPS) 
The Global Probability Score (GPS) is a feature of the HRT3. It was introduced as 
an operator independent algorithm since it did not require the contour line. GPA 
differentiates between normal and glaucomatous eyes by generating a three 
dimensional shape, as glaucoma develops the GPS model assumes that the retinal 
nerve fibre layer (RNFL) changes such that its curvature flattens as it thins and the 
cup enlarges and consequently, the slope of the neuroretinal rim steepens. The 
parameters from the best 3-dimensional model, which fits from the HRT normative 
database, then gives a probability of the individual disc being outside the normal 
range. The data produced has been extensively research in current literature with a 
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general consensus that it is at least as effective as MRA in prediction of glaucoma 
(Moreno-Montañés, Antón, et al. 2008), and is slightly better at identifying a normal 
disc (Strouthidis, Demirel, et al. 2010). But the GPS value, as a standalone predictor 
of glaucoma, is recommended to be interpreted with caution (Ferreras, Pajarín, et 
al. 2007). 
 
2.9.9  Topographic Change Analysis (TCA) 
The Topographic Change Analysis (TCA) analysis of HRT data evaluates the 
significance of the observed changes in baseline and follow-up, with reference only 
to the individual patients variance at a particular location, and not to values derived 
from the normative population data set. It is a statistical method to compare the 
topographic values in discrete areas of the image called super pixels, which contain 
4x4 (16 pixels) at two points in time. TCA does not require a contour line, or 
reference plane. TCA analysis is performed on the raw topography data and 
computes at each super pixel the probability of the difference in the two height 
values occurring by chance alone. When the TCA image is access placing the 
cursor at a point on the image gives a height difference and a probability score (p=) 
that the change could be down to chance. The variability of height measurements is 
greater at the edge of the optic cup and along blood vessels so the height variation 
is set to a higher value in the algorithm at these points.  
 
2.9.10 Assessing Visual Field Progression 
Visual field evaluation is a psychophysical test. It is designed to investigate the 
relationship between physical stimuli and perception of those stimuli. Like all 
psychophysical tests it is subject to a degree of variability. 
 
The visual field is a measurement of all that is available to one eye at a given time. It 
has been likened to a hill of vision surrounded by a sea of blindness. The visual field 
plot is an attempt to draw this hill of vision and assess any change. The algorithms 
applied to the visual field endeavours to attribute visual field loss either to a normal 
ageing change or suggest the probability of an alternative diagnosis. 
 
Standard Automated Perimetry (SAP) measures light sensitivity across various 
locations across the visual field. It is fundamental in the diagnosis and follow-up of 
glaucoma. Because SAP is not selective for a particular type of ganglion cell, and 
any ganglion cell may respond to the light stimulus, a substantial number of retinal 
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ganglion cells must die before development of visual field loss (Harwerth & Quigley 
2006). A 50% loss is often quoted before the onset of detectable visual field damage 
(Quigley 1982). This has since been review downwards to 25-35% death of retinal 
ganglion cells before evident field loss (Kerrigan–Baumrind, Quigley, et al. 2000). 
The reason for this large number of ganglion cells being lost before functional visual 
field loss is because the relationship is logarithmic, and a relatively large number of 
retinal ganglion cells must be lost before the threshold measurement detects the 
defect as outside normal limits. The variation of these two correlations may well be 
due to the difficult task of comparing recent visual fields, to post-mortem retinal 
tissue in patients. 
 
Study of post mortem retinas in glaucoma patients that compared retinal ganglion 
cell densities to static perimetric thresholds on a point-by-point basis showed that, 
on average, statistically significant abnormalities of visual sensitivity required neural 
loss of between 20-50% to occur, depending on retinal eccentricity. For any given 
level of neural loss there was a very large range of visual defects (Quigley, 
Dunkelberger, et al. 1989). 
A more recent correlation of retinal ganglion cells (RGC) utilised an estimate of RGC 
using SAP sensitivity thresholds and retinal nerve fibre layer thickness 
measurements obtained from spectral domain optical coherence tomography (SD-
OCT). The average RGC count for eyes with visual field defects were 652,057 ± 
115,829 which is significantly lower than the healthy eye count of 910,584 ± 142,412 
(P<0.001) which is an average loss of 28% (Medeiros, Lisboa, et al. 2013). This is a 
closer estimate to the lower value of Kerrigan who 25% ganglion cell loss with a 5dB 
loss in visual field sensitivity (Kerrigan–Baumrind, Quigley, et al. 2000). Medeiros 
went on to estimate that a minimum percentage loss of 17% was needed to cause a 
consistent visual field defect. This compared to a loss of 52% in an advanced 
glaucomatous field. 
 
Glaucoma is not consistent in its perimetric loss, and patients are not consistent in 
their attention to the perimetric test (Gillespie, Musch, et al. 2003). This is 
compounded by increasing age and other comorbidity’s e.g. cataract and macular 
degeneration. The problem with the diagnosis or assessment of glaucoma based on 
a patients’ visual field examination is the variability of both the pattern of visual field 
loss and their subjective responses. Despite this perimetry remains the third, in the 
core triad of diagnosis and monitoring of glaucoma disease. This triad of IOP, 
perimetry and optic disc assessment is the gold standard for all research involving 
glaucoma (Öhnell, Heijl, et al. 2016).  
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Glaucomatous visual field loss defined by the Hodapp classification (Hodapp, 
Parrish, et al. 1993) was adopted by the NICE guidelines in 2009. Field loss was 
divided into three areas, early, moderate and advanced. The evolution of glaucoma 
through these criteria was based on increase in mean defect and 5% probability of a 
defect in an increasing number of tested points. It is evident from the literature that 
no consensus exists regarding the best method for differentiating between stable 
visual field defects and variable field loss from progressive defects. Furthermore the 
relationship between structural and functional loss is not fully understood. 
 
Studies of laser induced, experimental glaucoma on monkeys have shown a much 
smaller variability in structure-function relationships when the criteria of static visual 
field testing, timing of collection and processing of retinal tissue was more tightly 
controlled (Harwerth, Crawford, et al. 2002) The general relationship suggested that 
when retinal ganglion cell losses were less than 50% there were small reductions in 
sensitivity but that functional and structural loss were not proportional. Thus these 
results suggested, that when translating retinal ganglion cell loss to visual field loss, 
other factors need to be included eg. redundancy and incomplete apoptosis. 
 
The purpose of perimetry is to indicate the site and extent of damage to the visual 
pathway. The key factor in glaucoma treatment is whether this field loss is 
advancing and therefore the potential adverse reactions from the treatment is 
worthwhile, or, alternatively, the field loss is static and no treatment is required. In 
1997 Joann Katz et al(Katz, Gilbert, et al. 1997)  suggested that only one in three 
eyes with glaucoma had any progressive field loss and that average changes in 
threshold sensitivities of less than 1dB/Year could not be detected with seven fields 
acquired over six years. Their advice that increased frequency of field tests would 
need to occur to detect small changes probably does not work in a busy glaucoma 
practice. 
 
A more sensitive visual field test in the form of blue target on yellow background 
(SWAP) may allow more accurate determination of progression, but, although this 
has been shown to be predictive of glaucoma damage (Johnson 1993) the 
increased inter-individual normal variability of SWAP limited its ability to be reliable 
in the practical decision of lifelong drug treatment by an ophthalmologist (Wild, 
Cubbidge, et al. 1998) The main reason for this unreliability is the blue stimulus is 
absorbed by the ocular media, mostly the crystalline lens. This absorption increases 
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with age and cataract formation; unfortunately it is age that is a known risk factor in 
glaucoma epidemiology. 
 
Senescence has proved to be a difficult factor to mitigate for in visual field loss (Spry 
& Johnson 2001). Spry et al found that age exerted an increasing effect on 
perimetric sensitivity. This has implications for determining a correcting factor for the 
normal visual field based on age and although a nonlinear function proved the best 
fit devices currently using a linear model would underestimate aging changes for 
older subjects and thus classify aging changes as pathological. 
 
The risk factors for glaucoma progression were summarised in an evidence based 
review paper published in 2013 (Ernest, Schouten, et al. 2013). The only two 
definite factors linked with glaucoma progression were age and neuroretinal rim disc 
haemorrhage. Although baseline visual field was a probable risk factor, it is listed 
alongside other equally weighted elements such as intraocular pressure and central 
corneal thickness. 
 
The key to detecting progression is the frequency of visual field measurement 
(Chauhan, Garway-Heath, et al. 2008), but the frequency varies significantly 
amongst hospitals and practitioners (Hertzog, Albrecht, et al. 1996), and often falls 
markedly below recommendations (Friedman, Nordstrom, et al. 2005). The 
recommendation set out by Chauhan was that six visual examinations should be 
carried out in the first two years  after diagnosis (Chauhan, Garway-Heath, et al. 
2008).  
 
In a recent survey of glaucoma specialists within the UK, the problem of 1 million 
appointments for glaucoma was considered against the NICE and research 
recommended six visual field examinations in the first two years (Malik, Baker, et al. 
2013). The survey was replied to by half of the glaucoma specialists currently 
practising in UK hospitals. Current decision making of visual field testing is decided 
by the clinician’s estimate of speed of glaucoma progression. It is acknowledged 
that six visual fields would yield useful data to estimate glaucoma progression but 
there are practical time and money barriers to implementing this as the accepted 
gold standard. 
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2.9.11  Interpretation of Visual Field Results 
This research exclusively used the Humphrey Visual Field Analyser and the StatPac 
statistics program to interpret results from consecutive fields. 
 
The Humphrey Stat Pac program performs three important functions  
“ 1/ it can point out suspicious areas that otherwise might not be evident until 
subsequent testing 
2/ it can identify areas that look suspicious but which, in fact, compare favourably 
with normal data 
3/ using results from a series of tests, Stat Pac can provide a highly sensitive and 
informative analysis of changes in the patient’s visual field over time “ (The Field 
Analyser Primer, Humphrey systems, Dublin, California). 
 
Visual fields are inherently noisy. The known difficulty of consistency of patient 
fixation is considered by the Humphrey Visual Field machine to be an excessive 
fixation loss when the blind spot tested has moved 20% of the time, but a research 
paper in 1990 concluded this was too high demand and that 33% was a more 
realistic value (Sanabria, Feuer, et al. 1991). This research has taken the value of 
33% and any field exam with fixation above this was discarded and repeated within 
two weeks. 
 
For interpretation of visual field the Hodapp et al glaucoma grading scale was used 
(see appendix)(Hodapp, Parrish, et al. 1993). 
 
2.9.12 Mean Deviation (MD) 
Mean Deviation represents the overall elevation, or depression, of patients overall 
field compared with the normal reference field. If the value is significantly outside the 
normal field for that patient’s age, then a p value is given. The p value suggests that 
less than this percentage of the normal population shows an MD larger than the 
value calculated. A significant MD suggests the patient has an overall depression, 
or, that there is a very deep or widespread loss in part of the visual field and not 
others. Unfortunately this variable is prone to influence by other factors and typically 
a cataract will reduce the MD value as it increases in density and reduces the 
overall sensitivity of the field.  
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2.9.13 Pattern Standard Deviation 
The Pattern Standard Deviation (PSD) is a measurement of the degree to which the 
shape of the patients measured field differs from the normal age corrected reference 
field. A low PSD indicates a smooth hill of vision and a high PSD suggests an 
irregular hill. To indicate the statistical significance of the calculated PSD a p value 
is assigned, as with MD this indicated the percentage of the population having a 
PSD numerical value larger than the printed result. The Pattern Standard Deviation 
(PSD) is a better statistical analysis for tracking localised field loss. 
 
2.9.14 Correlation of the HRT with the Visual Field 
The Heidelberg Retina Tomography is advertised as “ a proven essential tool for 
detecting and managing glaucoma, especially for assisting in the identification of 
pre-perimetric disease and tracking progression” (Heidelberg Engineering UK 
website www.heidelbergengineering.co.uk). It is thought that retinal ganglion cell 
death with subsequent change at the optic nerve head precedes the onset of 
glaucomatous field loss (Sommer 1991). The basis of the HRT scanner is to detect 
this change before a functional loss of vision, which is detectable with a visual field 
exam. The ability to recognise loss in the retinal ganglion cells separates the 
structure function relationship with glaucoma. The clinical decision to start a lifetime 
of treatment for glaucoma based on this measurement has not been accepted by 
the majority of ophthalmologists, and therefore, the reliance on a coincident visual 
field defect returns the HRT to a structure function connection. 
 
The HRT has been shown to detect neuroretinal tissue loss attributable to perimetric 
glaucoma (Wollstein, Garway-Heath, et al. 2000; Alencar, Bowd, et al. 2008). The 
effectiveness of the HRT measurements in prediction of glaucoma when compared 
to the gold standard of stereophotography has been shown to be equal but not 
superior to expert analysis (Weinreb, Zangwill, et al. 2010). The correlation of visual 
field to the HRT has been shown to be statistically significant with visual field MD 
value and  neuroretinal rim volume (Tole, Edwards, et al. 1998). More recent studies 
have shown only a more moderate comorbidity with visual field and two specific 
stereometric HRT values, rim area and rim volume (Danesh-Meyer, Ku, et al. 2006). 
This reduced relationship between visual field indices and optic nerve head 
parameters could be explained by the research suggesting that retinal ganglion cell 
losses when less than 50% had only a small reduction in sensitivity and this 
reduction in sensitivity was not proportional to the structural loss (Harwerth, Carter-
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Dawson, et al. 2004). They went on state that with greater degrees of neuropathy 
the structure function relationship was more systematic although with considerable 
variability. This would suggest a large degree of redundancy in retinal ganglion cell 
structure making a linear relationship between HRT and visual field exam an 
unreliable statistic. This reduced correlation between optic nerve head topography 
and visual field was shown for both angle closure and open angle glaucoma 
(Boland, Zhang, et al. 2008).  
 
 Current Research Correlation of HRT parameters with Visual Fields (MD) 
Regional Correlation of Structure 
and Function in Glaucoma 
Correlation Coefficient (P value) 
HRT and OCT in Normal, OHT and 
Glaucomatous Eyes correlation 
Coefficient (P value) 
Rim Area (mm2) 0.35 (0.0018) 0.49 (0.0001) 
Rim Volume 
(mm3) 
0.28 (0.0030) 0.43 (0.0001) 
Table 5 Current Research Correlation of HRT parameters and Visual Field (MD) 
The literature found the best correlation of HRT parameters with global visual field 
damage to be rim area and rim volume (Danesh-Meyer, Ku, et al. 2006; Mistlberger, 
Liebmann, et al. 1999). 
 
3.0 Blood Vessel Measurement in Glaucoma 
 
3.1 Aim of Study 
There are three questions that guided this research: 
1) how reliable are retinal vessel measurements with the HRT (assessed using 
Bland-Altman analysis) 
2) Assess vessel diameter differences between controls and patients with glaucoma 
and ocular hypertension 
3) Determine whether there is a change in the groups after a one year period 
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The HRT has an interactive tab within the computer software then enables a cursor 
to be place on the image acquired and measurements taken between any two 
points. This is a new method for measuring the diameter of blood vessels. This 
software is included within the HRT analysis program and is accessed by simply 
pressing the interactive tab GPS classification tab at the top of the screen. I 
hypothesise that the diameters of retinal blood vessels alter in glaucoma. 
 
Early diagnosis of glaucoma is critical to reduce the risk of permanent structural 
damage and irreversible vision loss occurring (Garway-Heath 2008). Currently, the 
diagnosis of glaucoma is made via a triad of tests; optic disc assessment, intra-
ocular pressure (IOP) and visual field examination (Anon 2009). These tests are 
looking for typical glaucoma traits in the form of nerve tissue loss at the optic disc, 
raised IOP with the potential to cause harm and a pattern of visual field loss typical 
of glaucoma. There are two other parameters not normally taken in a high street 
practice that can aid glaucoma diagnosis; central corneal thickness (CCT) and 
ocular perfusion pressure (OPP). 
 
OPP is defined as the difference between arterial and venous pressure. In the eye, 
venous pressure is equal to, or slightly greater than IOP. OPP can therefore be 
defined as the difference between blood pressure (BP) and IOP (Costa, Arcieri, et 
al. 2009). These values are gaining increasing significance in glaucoma literature; 
helping to explain why lowering of IOP past the assigned target level does not slow 
glaucoma progression (Quaranta, Katsanos, et al. 2013). In the Early Manifest 
Glaucoma Trial low systolic perfusion pressure, low systolic blood pressure and 
cardiovascular disease were predictors of glaucoma (Leske, Heijl, et al. 2007). 
 
3.2 Rationale 
The retinal vessels provide a unique opportunity to monitor microvascular changes 
by direct non-invasive visualisation. This simplicity of observation is enhanced by 
electronic methods of scanning and magnification, and because the vessels share 
similar anatomical and physiological characteristics with vessels in the brain and 
heart (Wong, Klein, et al. 2001), correlations can be drawn by observation of 
diameter and corresponding changes in either disease onset or progression. 
Generalised artery narrowing is an early feature of hypertensive retinopathy (Wong, 
Klein, et al. 2001; McClintic, McClintic, et al. 2010) narrowing is hypothesised to 
predict cardiovascular disease, mortality (Wong, Klein, et al. 2003; Gillum 1991) and 
even knee replacement (Hussain, Wang, et al. 2015). However, retinal arteriolar 
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narrowing is imprecisely quantified from direct ophthalmoscopy (Maestri, Fuchs, et 
al. 2007). 
 
The arterial supply of the adult optic nerve is derived completely from branches of 
the ophthalmic artery (chapter 2.1) The vascular theory of glaucoma proposes that 
optic nerve head blood flow is compromised (Flammer, Orgül, et al. 2002). This 
resultant ischemia can interfere with axonal nutrition and axoplasmic flow (Osborne, 
Ugarte, et al. 1999). A possible reason for this ischemia is an abnormality in blood 
vessel autoregulation, this would effect the ability of vessels to control ocular 
perfusion pressure (Sehi, Flanagan, et al. 2005). 
 
The normal optic disc vasculature does not leak; this is easily demonstrated with a 
fluorescein angiogram (Figure 20). 
 
 
Figure 20 Fluorescein Angiography normal Optic Disc and fundus, dark lines-veins, white lines-
arterys 
(http://www.medicine.uiowa.edu/uploadedImages/Departments/Ophthalmology/Cont
ent/Patient_Care/Imaging_Services/FA_Fig2(1).jpg) 
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The perfusion of any organ is dependant on, perfusion pressure, vascular resistance 
and local blood viscosities. An alteration in the diameter of blood vessels 
physiologically regulates the vascular resistance. There are two principle ways in 
which vessel diameter is changed metabolically and myogenically. Both of these 
mechanisms have been shown to be present in the retina (Bill 1985).  
 
Current evidence suggests that an endothelium dependant mechanism is a key 
element in hypoxia-induced vasodilation. The most likely mediators being 
prostaglandins (Busse, Forstermann, Matsuda, & Pohl, 1984; Busse, Pohl, Kellner, 
& Klemm, 1983). This would suggest that the prostaglandin Xalatan could influence 
vessel diameter in addition to the lowering of IOP. Thus it can be hypothesised that 
in patients developing glaucoma, their retinal blood vessels should decrease in 
diameter and in patients being treated for glaucoma with Xalatan, blood vessel 
diameter constancy would suggest disease stability. 
 
The second factor of myogenic regulation is affected by blood pressure and that 
although the exact mechanism is still under investigation the physical contraction is, 
at least partly, mediated by endothelial factors (Davies & Tripathi 1993). The 
irregular diurnal variation of IOP in a glaucomatous eye might then be affected by a 
corresponding variation in BP over 24 hours. This large diurnal variation in IOP has 
been shown to be an independent risk factor for glaucoma (Asrani, Zeimer, et al. 
2000). By making an assessment of the ocular health of the patients eye alongside 
the retinal vessel diameter our research aims to determine if there is a retinal 
vascular element that is measurable in a high street optometry practice, in the hope 
this will further aid glaucoma diagnosis. Scanning laser tomography will be used to 
quantify blood vessel diameter change longitudinally in addition to estimation of 
ocular perfusion pressure. 
 
3.3 Methods 
This research took place at an independent Optometrists in Northern Ireland. Each 
volunteer was required to attend high street practice four times. The patient was 
examined with an extended eye examination on their first visit involving prescription 
determination, keratometer readings, IOP with a Goldman tonometer, stereoscopic 
fundus examination using a volk lens, gonioscopy to evaluate the anterior angle, slit-
lamp exam of the anterior eye, central corneal thickness measurement using an 
ultrasound pachymeter, blood pressure measurement, scanning laser tomography 
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of the optic nerve head using the HRT and finally a full threshold field examination 
(see Section 2.9.10 for more details). 
 
A second visit took place one week after the first appointment to repeat the initial 
visual fields. The third and fourth visits repeated the protocols of the first and second 
visits respectively and took place one year after initial two visits. The study was 
conducted in adherence to the tenets of the Declaration of Helsinki and was 
approved by the Aston University Ethics Committee. 
 
3.4 Sample 
The volunteer participants were recruited from a high street optometrist patient 
base, presently attending for routine eye care. Three patients groups were targeted 
for recruitment (40 volunteers in each group) aged between 30-70 since this is the 
group most prone to glaucoma. Assuming normally distributed data and a blood 
vessel variability of 30µm the sample size required to demonstrate differences in 
blood vessel diameter would be 16. Assuming for drop out in the longitudinal study, 
40 patients were aimed initially recruited in each group (See Appendix; Audiology & 
Optometry Ethics Form). 
 
3.5 Sample Categorisation 
The volunteers were divided into three groups 
• Normal; this group was defined as participants without any general health 
comorbidity that may affect vessel diameter (diabetes, unstable blood 
pressure, Raynaud’s syndrome), visual field (epilepsy, history of anterior 
ischaemic neuropathy) or neuroretinal rim changes at the optic disc (Multiple 
sclerosis, dementia) In addition, their ocular history was without incident that 
may indicate instability of vision or visual field (recent artery or vein 
occlusion, active dry or wet macula degeneration, significant cataract 
effecting mean deviation or best corrected visual acuity) Against this stable 
ocular and general health history their IOP consistently measured below 
21mmHg at any point during daytime waking hours 
• Ocular Hypertensive; this group had the same criteria as the normal group 
except for the dividing factor that the IOP should measure above 21mmHg 
during daytime hours, meeting the classification requirements of the NICE 
guidelines of an Ocular Hypertensive 
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• Glaucoma; the diagnosis of primary open angle glaucoma by an 
ophthalmologist with a specialist interest in glaucoma and considered to be 
stable on the specific medication of Latanoprost (Xalatan 0.005%) The 
condition of stability was accepted if the patient was on routine recall of one 
year and the medication had not been changed in the last two years. 
  
3.6 Inclusion/Exclusion Criteria 
The recruited patients were placed into three categories; 
 
1/ Normal: defined as a patient with no glaucomatous visual field loss, optic disc 
changes suggestive of glaucoma and IOP<21mmHg 
 
2/ Ocular Hypertensive: defined as a patient with no glaucomatous visual field loss, 
no optic disc changes suggestive of glaucoma and IOP>21mmHg 
 
3/ Glaucoma; defined as a patient diagnosed with primary open angle glaucoma by 
an ophthalmologist, currently under review, and being treated exclusively with 
Latanoprost (Xalatan (0.005%), a prostaglandin analogue) inserting one drop at 
night. 
 
The NICE directive made a requirement for all optometrists to refer patients who 
measured IOP over 21mmHg (no instrument specified) (Edgar, Romanay, et al. 
2010). N.Ireland has put in place a referral refinement scheme whereby a patient 
with an IOP greater than 21mmHg was asked to return and the IOP repeated with a 
Goldmann tonometer. If the reading was still over 21mmHg then they are referred 
into the hospital eye service for screening. All patients in the hypertensive group 
recruited for this research followed this protocol, and had either been seen and 
discharged, or were under review by an ophthalmologist. 
 
Ethnicity could conceivably be a complicating factor in blood vessel diameter 
change; research has suggested different progression rates of glaucoma despite 
similar IOP with the suggested explanation relating to its vascular aetiology. To 
reduce the possibility of ethnic variability, all patients recruited for this research were 
Caucasian, which was also the dominating ethnicity in the recruitment practices, 
98.58% (Curran & Dooley 2014).  
 
 
  54 
General exclusion criteria included 
 
• Refractive correction greater than +/- 4.00DS and 2.00DC 
• Medication known to influence the visual field eg Vigabatrin-used for 
treatment epilepsy, or Hydroxychloroquine which has the potential to cause 
paracentral scotomas 
• Medication known to influence the visual field eg Vigabatrin-used for 
treatment epilepsy, or Hydroxychloroquine which has the potential to cause 
paracentral scotomas 
• Ocular Disease known to effect visual field eg. Retinitis Pigmentosa, 
Chorioretinitis 
• Diabetic patients or other retinal disease 
• Patients with significant lens opacity the Lens Opacities Classification 
System III was considered (Tan, Loon, et al. 2008) but in practice a best 
corrected visual acuity of 6/12 was considered the minimal vision required 
• Closed angle glaucoma and individuals with anterior angles are at risk of 
closure, the angles were evaluated using a Goniscopy lens and the Shaffer 
system 
The inclusion criteria relating to the glaucoma group was that they were being 
treated with Latanoprost (Xalatan (0.005%), a prostaglandin analogue).  
 
All glaucoma patients were outside the normal limits on the glaucoma hemifield test, 
whilst all normal and OHT were within normal limits. The glaucoma group were all 
under the care of an ophthalmic surgeon with a special interest in glaucoma. All 
were being treated with Xalatan only, and inserted one drop in each eye at night. All 
glaucoma patients were under one year review for glaucoma and considered stable 
at their last review. They were diagnosed and referred for glaucoma over ten years 
prior to baseline field for this research and since the practice is only ten years old 
there are no records to define the patient at initial diagnosis as high, or low tension 
glaucoma. There were no patients with iridotomy holes indicating treatment for 
closed angle glaucoma. The severity of the glaucoma, defined as functional loss of 
the visual field is illustrated using the Hodapp-Parrish-Anderson classification 
system based on the Humphrey Visual Field analyser score and one other criteria 
(Hodapp, Parrish, et al. 1993) (see Appendix Glaucoma Grading Scale Hodapp-
Parrish-Anderson). Using this scale and considering both the MD and PSD values 
together the glaucoma group could be defined as early glaucoma, which is stable. 
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The treating ophthalmologist was notified if any significant glaucoma progression 
occurred in any of the volunteers during the duration of the research. 
 
3.7 Informed Consent 
See Appendix; informed consent sheet 
 
3.8 Recruitment and sequence of visits 
Each volunteer was required to attend four times. The patient was examined with an 
extended eye examination on their first visit involving prescription determination, 
keratometer readings, IOP with Goldmann, stereoscopic fundus examination using 
volk lens, gonioscopy to evaluate anterior angle, slit-lamp exam on anterior eye, 
central corneal thickness measurement using an ultrasound pachymeter, blood 
pressure measurement, scanning laser retinal tomography of the optic nerve head 
using HRT and finally a full threshold visual field examination. The second visit took 
place approximately one week after the first visit during which the visual field 
examination was repeated in order to reduce the learning effect of perimetry. 
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• General Health History 
• Family Ocular History 
•  List Medicines taken 
• Dilated Binocular Fundoscopy 
• Gonioscopy 
• Pachymetry 
• Goldmann Tonometry 
• Heidelberg Retinal Topography Imaging 
• Visual Field test, 30-2 Sita full threshold 
• Omron Blood Pressure testing 
Patient first 
visit 
 
 
Repeat of Visual Field 
Visual Field Test, 30-2 Sita full Threshold 
Patient 
third visit 
one year 
later 
Patient 4 
visits? 
STOP 
Patient 2 
visits? 
recall 
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3.9 Capture HRT Image 
The quality of the HRT image is a key factor in measuring blood vessels to 
0.011mm. Heidelberg recommends this begins with choosing a suitable lens power 
from the magnetic clip on lenses, this is calculated as a best form lens from entering 
the volunteer’s spectacle prescription into the patient details form and the HRT will 
suggest a best spherical lens. The HRT also has a magnetic clip-on astigmatic for 
prescriptions over +/- 1.00DC. The corneal curvature is entered so that 
magnification can be accounted for should the patient undergo any future corneal 
surgery. All volunteers in this research had refractions under +/- 4.00 dioptres 
spherical and less than -2.00D cylinder, with no history of corneal surgery or 
diagnosis of corneal dystrophy. This minimised any change in magnification effects 
on blood vessel measurement. The optic disc was then aligned. The optic disc is 
centred by first directing the volunteer to fixate on a green flashing light inside the 
camera, the laser is then centred to enter the pupil, the live image should appear on 
screen. Any laser light falling on the iris should be avoided as this will lead to a 
crescent shaped shadow on the acquired image. The image is more finely tuned 
using the focusing dial; this value is automatically recorded with the scan and on 
subsequent images if this number changes by more than two dioptres, then a 
warning notice is flashed up. During this data collection for this research patients 
were more readily setup with correct position by getting then to follow and focus on 
the fixation white light attached to the HRT machine and mounted on a movable 
stalk. The understanding of an instruction to “look at the white light” or “follow the 
white light” as the optic disc image was centred left no room for misinterpretation by 
the patient, this lead to quicker image acquisition. The optic disc was centred inside 
a green target area superimposed on the live image. The line topography at the 
base of the scan gave an indicator of vessel edge start and finish points. The 
reflection of the vessel wall allow determination of grouping, either vein or artery. 
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Figure 21 HRT Image Capture 
 
 
3.10  Statistical Analysis 
Statistical analysis was done on IBM SPSS version 22.  
 
3.12  Sample Characteristics 
Across all groups, the average time between appointments was 360 days with a 
standard deviation of 135 days. 
 
Before applying statistical tests to examine for differences between and within 
groups, the data was tested for normality using Shapiro Wilk test. When the output 
is significant >0.05, then the data distribution is considered to be normal. The α level 
was set to α= 0.05. The retinal vessel analyses are the primary outcome of this 
research and Shapiro Wilk testing of superior and inferior CRAE and CRVE showed 
normal distribution. Consequently, parametric statistics were used to explore for 
differences between and within the normal, glaucoma and ocular hypertensive 
groups. 
 
  59 
A Shapiro-Wilk test was done for for the central retinal artery RE baseline reading. 
All three groups were to be normally distributed (p>.05); a visual inspection of the 
histogram and Q-Q plots also showed the results to be normally distributed. 
Skewness and Kurtosis are shown in table 6.   
 
Right Eye Skewness (standard error) Kurtosis (standard error) 
Normal 0.764 (0.421) 0.286(0.821) 
Glaucoma 0.548(0.564) -0.002(1.091) 
OHT 0.467(0.448) 0.172(0.872) 
Table 6 Skewness and Kurtosis of CRAE RE Baseline Reading 
A Shapiro-Wilk test was done for the central retinal artery LE baseline reading. All 
three groups were normally distributed (p>.05): a visual inspection of the histogram 
and Q-Q plots showed the results to be normally distributed. Skewness and Kurtosis 
are shown in table 7. 
 
Left Eye Skewness (standard error) Kurtosis (standard error) 
Normal -0.279(0.564) -0.099(1.091) 
Glaucoma 0.387 (0.421) -0.34 (0.821) 
OHT 0.253(0.448) -0.741(0.872) 
Table 7 Skewness and Kurtosis of CRAE LE Baseline reading 
In all tests using the one-way ANOVA calculation, homogeneity of variances was 
preformed to determine normal sampling of data and p confirmed at p>.05 before 
accepting the result from the ANOVA table. 
 
103 subjects were recruited with 74 completing the second visit one year after first 
collection of data. The age distribution is shown in table 8. 
 
 Mean Age N Standard Deviation 
Normal 67.4 32 8.72 
Glaucoma 72.2 16 5.44 
OHT 67.48 27 6.63 
Table 8 Average Age of Volunteers in this research 
The distribution of males (n=34) and female (n=40) was tested for normality. 
Shapiro-Wilk test (p<0.05) showed the distribution of male/female was not normal, 
but both groups fell within the z-value of -1.96-+1.96. The skewness for male -0.435 
(standard error 0.403) and kurtosis -0.863 (standard error 0.788) were normal and 
for female wqs normal with a  skewness -0.89 (standard error 0.374) and kurtosis    
-1.337 (standard error 0.733). 
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4.0 Results 
 
4.1 Continuity of Measurement, Bland-Altman Plot 
The gold standard in data research is a blind, randomised collection of data. All the 
patients in this research were known, and although measurements were taken of 
vessel diameter without reference to previous year, the assessment of ocular health 
for the patient could bring a bias to vessel measurement. There was no potential for 
a second observer to rule out this bias. Taking a sample of ten volunteers from both 
the normal and glaucoma group, a second measurement of artery diameter was 
recorded. This artery measurement was then compared to original measurement 
and a Bland Altman graph plotted, this would determine if there was a significant 
difference and therefore lack of continuity in vessel diameter. 
   
 Masked Artery Measurement, Repeatability Comparison n=10 
Original Measurements  Comparison Measurements 
RE LE RE LE 
Normal 301.5 (41.5) 269.9 (60.97) 301.6 (22.41) 273.9 (35.27) 
Table 9 Masked Artery Measurement, Repeatability Comparison, Normal group 
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Figure 22 Bland Altman plot RE artery, normal group, red line mean, black lines upper and 
lower 95% confidence 
 
A one sample t-test for the RE artery diameter difference between a second blind  
re-measurement of a sample gave the values t=1.999, df=9 and a non significant 
p=0.077. This would demonstrate that there is no significant difference between the 
diameter measured at baseline and a second measurement of the baseline to 
determine if there was difference attributable to observer error. The scatter plot 
showed all values lying within the 95% confidence limits. A linear regression 
calculation showed t=2.015 and t=0.079 showing there was no statistical significant 
proportional bias. 
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Figure 23 Bland Altman plot LE artery diameter red line is mean, black lines upper an lower 95% 
confidence limits 
A one sample t-test for the LE artery diameter difference gave a t=0.939, df=9 and 
p=0.372 indicating there is no significant difference between the baseline 
measurement and a second measurement taken to assess observer error. The 
scatter plot shows all values lying within the 95% confidence limits. A linear 
regression calculation showed t=-0.446 and a non-significant p=0.667 indicating no 
statistical proportional bias. 
 
 Masked Artery Measurement, Repeatability Comparison n=10 
Original Measurements  Comparison Measurements 
RE LE RE LE 
Glaucoma 262.19 (20.46) 246.25 (38.53) 262.7 (21.71) 246.0 (42.64) 
Table 10 Masked Artery Measurement, Repeatability Comparison Glaucoma group 
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Figure 24 Bland Altman plot RE artery, glaucoma group, red line mean, black lines upper and 
lower 95% confidence 
 
A one sample t-test for the RE artery diameter difference gave t=0.909, df=9 and 
p=0.387 indicating there is no significant difference between baseline measurement 
and a second baseline measurement taken to assess observer error. A linear 
regression calculation showed t=-.541 and a non-significant p=0.603 indicating no 
proportional bias. 
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Figure 25 Bland Altman plot LE artery diameter Glaucoma group red line mean, black lines 
upper and lower 95% confidence limits 
 
A one sample t-test for the RE artery diameter difference gave t=-1.414, df=9 and 
p=0.0191 indicating there is no significant difference between baseline 
measurement and a second baseline measurement taken to assess observer error. 
A linear regression calculation showed t=0.891 and a non-significant p=0.399 
indicating no proportional bias. 
 
4.2  Artery Diameter Comparison 
In glaucoma the superior visual field is more frequently affected compared to 
inferior. The interactive tab on the HRT software makes the separation of these two 
hemispheres relatively easy. This research then expanded the normal consideration 
of circumferential vascular analysis to a more detailed consideration of whether 
diameter changes were more pronounced in the superior vascular network 
compared to the inferior. 
The group mean superior and inferior CRAE values are shown for each group at 
baseline and one year later for right (Table 11) and left (Table 12) eyes. 
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 RE Group Mean superior and inferior CRAE (μm) 
Baseline 1 Year After Baseline 
Superior Inferior Superior Inferior 
Normal 212.7 (35.60) 199.9 (30.84) 207.3 (31.05) 201.7 (20.71) 
Glaucoma 165.8 (30.64) 184.6 (21.26) 161.5 (31.32) 182.6 (21.26) 
OHT 186.1 (23.81) 183.4 (23.41) 178.1 (24.89) 179.3 (25.79) 
Table 11 Group Mean superior and inferior CRAE for RE baseline and one year later 
 
In comparison between superior and inferior at baseline there was no significant 
difference in any groups (normal p=0.07, glaucoma p=0.09, OHT p=0.63). Using 
paired t-test, after one year there was no significant difference between superior and 
inferior (normal p=0.42, OHT p=0.83, glaucoma p=0.06). 
 
At baseline the RE superior artery glaucoma group mean showed a reduced 
diameter of 46.91μm compared to the normal group (p=0.009) and 20.30μm 
compared to the OHT group (p=0.04). The OHT group also showed a smaller 
diameter compared to normal group of 26.61μm (p=0.001) For the RE inferior 
artery glaucoma group there was a significant difference between smaller diameter 
arteries OHT group, to normal, of 16.49μm (p=0.02), no other significant differences 
between groups (figure 26). 
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Figure 26 RE Comparison Artery Diameter Superior and Inferior at baseline 
 
 
 LE Group Mean superior and inferior CRAE (μm) 
Baseline 1 Year After Baseline 
Superior Inferior Superior Inferior 
Normal 190.6(34.04) 190.1(31.43) 186.0(35.55) 193.5(21.56) 
Glaucoma 156.7(23.42) 156.1(26.36) 147.5(23.45) 156.1(27.64) 
OHT 174.9(33.08) 173.3(28.21) 167.6(35.96) 169.9(25.88) 
Table 12 Group Mean superior and inferior CRAE for the LE at baseline and after one year 
 
Using paired t-test, in comparison between superior and inferior LE there were no 
significant differences between any of the groups (normal p=0.95, glaucoma p=0.15, 
OHT p=0.85), table 12. 
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Figure 27 LE Comparison Artery Diameter Superior and Inferior at baseline 
Using one way ANOVA to compare between groups in the LE, at baseline the 
superior glaucoma artery had the smallest diameter, compared to the larger OHT 
this was not significant (18.24 p=0.07), but, the normal compared to glaucoma was 
larger by a mean of 33.93μm, and this was significant (p=0.001). The OHT was 
smaller compared to the normal but this was not significant (15.69μm p=0.06). The 
inferior artery also had the glaucoma group as the smallest, this was only significant 
compared to normal (38.47μm p=0.00) but not the OHT group (20.06μm p=0.06) In 
contrast to the superior, the inferior artery, had a significantly smaller diameter in the 
OHT group, compared to normal (18.41 p=0.04) 
 
 Paired Differences t-Test Mean (SD, p= μm) 
Baseline CRAE compared to 1 Year After Baseline 
RE Superior LE Superior RE Inferior LE Inferior 
Normal df (31) 5.43(21.20,0.16) 4.65(17.07,0.14) -1.75(20.18,0.63) -3.32(16.5,0.27) 
Glaucoma df16 4.31(17.73,0.35) 9.19(14.19,0.02) 1.94(13.68,0.58) 0.01(13.54,0.98) 
OHT df (27) 7.96 (21.3,0.06) 7.37 (13.8,0.01) 4.11(17.25,0.23) 6.44(14.89,0.03 
Table 13 Paired t-test differences R&L, Superior & Inferior CRAE 
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Using table 12 to summarise an overall t-test comparison between baseline and one 
year for both right and left CRAE diameter measurements, there are three 
significant values; For glaucoma, the LE superior artery has reduced in diameter, 
but for the LE OHT group, both inferior and superior arteries have reduced in 
diameter. 
 
Using an independent t-test to compare baseline RE with baseline LE, this showed 
not significant differences between right and left eye at baseline (table 14) 
 Independent t-test compare RE & LE CRAE (μm) 
Baseline (df,t,p=) 
Superior Inferior 
Normal (61)(t=2.517 p=0.517) (60)(t=0.058 p=0.861) 
Glaucoma (30)(t=0.946 p=0.443) (30)(t=3.359 p=0.535) 
OHT (52)(t=1.497 p=0.247) (52)(t=1.439 p=0.445) 
Table 14 Independent t-test to compare RE & LE CRAE 
 
The veins have not carried any weighting in current research to determine a 
connection with glaucoma onset and progression. The veins diameters were 
measured in this research, as with the artery diameters, to determine if the results 
followed the generally non-significant values from reports into vein diameter change 
aiding glaucoma diagnosis and prognosis. 
 
 RE Group Mean Superior and Inferior CRVE (μm) 
Baseline 1 Year Later 
Superior Inferior Superior Inferior 
Normal 250.6 (45.58) 230.3 (41.26) 250.09 (44.39) 227.4 (39.24) 
Glaucoma 231.6 (35.49) 210.7 (46.82) 216.8 (23.25) 215.9 (41.84) 
OHT 247.1 (34.81) 228.6 (47.78) 236.3 (28.64) 220.8 (48.09) 
Table 15 RE Group Mean Superior and Inferior CRVE 
The glaucoma group RE superior vein reduced in diameter, and this was shown to 
be significant (14.8 p=0.05), the other two groups had no significant change in the 
superior vein diameter. The RE inferior also reduced in diameter (7.85 p=0.01) but 
both the normal and OHT had no significant change. Between groups in the RE 
superior vein only the glaucoma being smaller in diameter than the normal showed 
a significant statistical difference (34.06μm p=0.02).  
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 LE Group Mean Superior and Inferior CRVE (μm) 
Baseline 1 Year After Baseline 
Superior Inferior Superior Inferior 
Normal 244.0 (44.59) 229.8 (25.81) 248.4 (16.71) 230.0 (25.96) 
Glaucoma 203.0 (36.25) 195.9 (27.03) 202.1 (28.03) 194.7 (24.17) 
OHT 230.4 (40.86) 218.0 (35.79) 224.1 (38.63) 217.7 (35.29) 
Table 16 LE Group Mean Superior and Inferior CRVE 
The LE superior and inferior baseline diameter showed no statistical difference 
between groups. 
 
4.3  Global Artery Comparison 
 
 Global Artery Comparison Baseline and One Year 
Baseline μm (SD) 1 Year After Baseline μm (SD) 
RE LE RE LE 
Normal 302.65 (41.74) 278.61 (36.53) 303.29 (38.91) 277.87 (33.92) 
Glaucoma 262.19 (20.47) 246.25 (38.53) 257.81 (23.40) 236.56 (38.04) 
OHT 271.89 (29.60) 260.00 (35.03) 262.78 (34.83) 249.56 (37.07) 
Table 17 Global Artery Change Baseline and One Year 
 Global Artery Change Baseline and One Year μm (t=, p=) 
 
RE 
 
LE 
Normal -0.001 (-0.322, 0.75) 0.001 (0.210, 0.83) 
Glaucoma 0.004 (1.083, 0.296) 0.01 (3.079, 0.008) 
OHT 0.009 (2.175, 0.039) 0.01 (3.114, 0.004) 
Table 18 Paired T-test on Change of Artery Diameter Baseline and One Year 
A paired sample t-test on global artery measurement change between baseline and 
one year showed the expected no statistical significance normal group. The 
Glaucoma group was also stable RE, but the Hypertensive group and LE Glaucoma 
group showed statistical significant change in artery diameter change.  
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5.0 HRT Parameters 
Although optic disc size is not linked with glaucoma disease, the area of the disc is a 
confounding factor in judgement of neuroretinal rim loss and determination of either 
disease beginning or progression. This research reduced the effect of optical factors 
by excluding high spherical powers and high cylinders. It is useful to have a baseline 
mean to observe disc area in each group (table 19) 
  RE Mean Disc 
Area (mm2)(sd) 
LE Mean Disc 
Area (mm2)(sd) 
N 
Normal 1.84 (0.43) 1.82 (0.46) 32 
Glaucoma 1.66 (0.35) 1.63 (0.26) 16 
OHT 1.85 (0.37) 1.76 (0.38) 27 
Table 19 Group Mean Disc Area (mm2) 
Although the glaucoma group was the smallest disc area in both right and left eyes 
compared to normal and OHT, one way ANOVA showed no significant difference 
between groups (glaucoma/normal p=0.112, glaucoma/OHT p=0.102, normal/OHT 
p=0.91) It was noted that the normal had the greatest standard variation in area, 
with glaucoma the smallest, which as a cross-section of optic discs, fits with the 
difficulty of judging neuroretinal rim normality across a range of disc areas. 
 
The HRT machine divides up the optic nerve head into six segments. Both the 
Nasal and Temporal segment are approximately 100’deg each. The remaining four 
sections totalling 160’deg are split evenly between superior temporal, superior 
nasal, inferior temporal and inferior nasal. This is shown in fig.28 & 29 
 
 
Figure 28 Segments of optic disc corresponding to visual field plot (Danesh-Meyer, Ku, et al. 
2006) 
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Figure 29 Map of Visual field RE relating to Optic Nerve Head (Danesh-Meyer, Ku, et al. 2006) 
 
For the purposes of research the superior hemifield in blood vessel measurement is 
taken to correspond to superior temporal and superior nasal with the inferior 
hemifield mapping to inferior temporal and inferior temporal. 
 
The HRT machine produces volume values assigned to each of these sections. For 
the purpose of glaucoma in this research the nasal and temporal sections are have 
not been considered. This cross-sectional relationship is a useful first approximation 
for the longitudinal relationship between structure and function in patients. 
 
 RE Group Mean Volume Superior and Inferior 
Baseline (μm3) 1 Year Later (μm3) 
Superior Inferior Superior Inferior 
Normal 84.7 (31.62) 93.8 (45.21) 80.3 (33.26) 90.9 (42.23) 
Glaucoma 63.1 (29.15) 80.6 (42.81) 63.8 (23.06) 75.0 (37.24) 
OHT 98.1 (35.63) 95.9 (42.47) 100.0 (37.42) 91.9 (37.63) 
Table 20 RE Mean Volume Superior and Inferior Optic Disc 
The glaucoma group was smaller in RE rim neuroretinal rim volume for both 
superior and inferior aspects. This reduced volume was only statistically significant 
in comparison between glaucoma and OHT superior (36.25μmm3 p=0.001). The 
normal group rim volume was smaller than the OHT group and this was significant 
in the superior (19.69μmm3 p=0.02). The inferior rim was not significant in any 
comparison combination. Paired t-test statistics comparing baseline and one year 
later showed a no significant difference in normal group rim volume RE either 
superior (p=0.114) or inferior (p=0.202). In the glaucoma group there was no 
significant change in rim volume RE superior (p=0.860) or inferior (p=0.057). The 
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OHT group showed no significant difference RE superior (p=0.593) or inferior 
(p=0.133). 
 
 LE Group Mean Volume Superior and Inferior 
Baseline (μm3) 1 Year Later (μm3) 
Superior Inferior Superior Inferior 
Normal 83.1 (46.59) 101.9 (46.59) 78.1 (39.63) 90.9 (44.31) 
Glaucoma 78.1 (39.63) 90.0 (44.31) 76.3 (36.96) 72.5 (57.91) 
OHT 99.3 (39.90) 96.7 (33.51) 100.0 (37.42) 91.9 (37.63) 
Table 21 LE Mean Volume Superior and Inferior Optic Disc 
The LE glaucoma group had the smallest volume of the three groups at baseline; in 
a one way ANOVA between groups at baseline there was a significant difference 
when comparing glaucoma to OHT (34.49 p=0.005) and in comparing OHT to 
normal (22.62 p=0.026) but no significant difference when in comparing glaucoma to 
normal. Using a paired t-test to compare between baseline and one year later there 
was no significant change in LE normal group superior (p=0.306) but there was a 
noted change decrease in volume inferiorly (10.94μmm3 p=0.004). In the glaucoma 
group LE neither the superior (p=0.222) or inferior (p=0.784) had any change. The 
OHT group had no significant change in either rim volume superior (p=0.694) or 
inferior (p=0.593) aspects.  
 
A total neuroretinal rim volume was calculated to see if any change was 
approximately equal to superior or inferior rim volume in order to justify the segment 
comparison to artery diameter change. 
 
 Total Neuroretinal Rim Volume  
Baseline (μm3)(sd) 1 Year Later (μm3)(sd) 
RE LE RE LE 
Normal 310.6 (112.48) 338.4 (113.79) 297.2 (109.4) 306.8 (100.91) 
Glaucoma 263.1 (100.61) 245.6 (141.47) 255.5 (85.56) 235.6 (109.48) 
OHT 335.9 (116.16) 331.1 (119.11) 330.7 (108.74) 336.1 (107.55) 
Table 22 Total Mean Volume Optic Disc µmm3 baseline and one year later 
 
When comparing between groups at baseline there was a significant reduction in 
volume of the glaucoma group compared to the OHT group in both RE (72.80 
p=0.04) and LE (85.49 p=0.02). In both eyes the other group comparisons were not 
significant. Performing a paired t-test between baseline and one year later the 
glaucoma group had no significant difference in either RE (p=0.41) or LE p=0.63). 
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The OHT group also showed no change RE (p=0.68) LE (p=0.59) The normal group 
was unchanged in the RE (p=0.11) but the LE did show a statistically significant 
reduction in volume (p=0.01).  
  Group Mean Rim Area (μm2)(sd) 
Baseline 1 Year Later 
RE LE RE LE 
Normal 1217.8(264.83) 1243.9(249.37) 1215.0(281.33) 1266.1(259.03) 
Glaucoma 1215.0(264.83) 965.0(266.91) 1045.0(201.86) 948.1(274.23) 
OHT 1270.4(207.5) 1207.4(250.02) 1262.6(200.57) 1203.7(248.68) 
Table 23 Group Mean Rim Area (µm2) 
Using one-way ANOVA between groups at baseline the RE glaucoma was 
significantly smaller than the OHT (225.37 p=0.003) and normal (172.81 0.018) but 
not significant for normal compared to OHT (525.6 p=0.391). For the LE glaucoma 
was significantly reduced in area compared to both the normal (278.87 p=0.001) 
and OHT (242.41 p=0.003) but the OHT was not significant different to the normal 
(36.46 p=0.586) In comparing rim area with a paired t-test there was no significant 
difference between baseline and one year in any of the groups. 
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6.0 How do all the Parameters Link? 
This research was based on determining the change in vessel diameter over time 
with the hypothesis that this change was related to glaucoma. In order to compare 
any relationship between the different variables measured a linear regression 
calculation was carried out. 
All of the calculations were based on change between baseline and one year. Using 
linear regression the results of artery diameter change were compared between the 
major parameters of IOP, MD, PSD and Neuroretinal rim volume. 
Because the participant numbers were relatively low, then heteroscedasticity was 
tested for each group to determine normal distribution and additionally a scatter plot 
was done to check for homogeneity of variance.  
6.1 Neuroretinal Rim Volume and Artery Diameter 
Pearson’s correlation showed that there was no correlation between RE rim volume 
loss and artery diameter reduction for the glaucoma group. There was a normal 
distribution of data (Fig 30). The change of neuroretinal rim volume RE was not 
statistically significant when comparing to artery diameter reduction (F=0.68 t=0.825 
p=0.423). 
 
Figure 30 Normal Distribution of linear regression comparing Rim Volume Change to Artery 
Diameter change RE 
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The scatter plot showed a bird’s nest pattern showing data was randomly distributed 
(fig 31). 
 
Figure 31 Scatterplot of Rim Volume RE change against RE artery diameter change to show 
data randomly distributed 
 
Pearson’s correlation showed no correlation between LE rim volume loss and artery 
diameter reduction. There was a normal distribution of data (fig 32). The change of 
neuroretinal rim volume LE was not statistically significant when comparing to artery 
diameter reduction (F=0.932 t=0.965 p=0.351). The scatter plot showed a birds nest 
pattern showing data was randomly distributed (fig 33). 
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Figure 32 Normal Distribution of data for LE rim volume change compared to artery diameter 
change Glaucoma group 
 
Figure 33 Scatter plot showing random distribution of change in neurofiber rim volume 
compared to artery diameter change LE Glaucoma group 
Pearson’s correlation was not significant between neurofiber rim volume loss and 
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artery diameter reduction RE normal group, there was normal distribution of data, 
and a scatterplot showed the data to be randomly distributed. The change of the 
neurofiber rim volume was not statistically significant (F=2.687 t=1.639 p=0.112).  
 
Pearson’s correlation for the normal group was significant between neurofiber rim 
volume loss and artery diameter reduction LE (t= 2.258 p=0.032). There was normal 
distribution of data, and a scatterplot showed the data to be randomly distributed, 
the P-P line showed good adherence to the regression line (fig 31). Although the rim 
volume change appeared to be connected to the reduction in artery diameter the 
confidence limits were large (CI lower 0.115 to upper 2.329). 
 
 
Figure 34 P-P plot showing good adherence to regression line for LE  change in artery diameter 
compared to rim volume for Normal Group 
 
Pearson’s correlation for the Hypertensive group RE was significant in neurofiber 
rim volume reduction when compared to artery diameter reduction RE (p=0.05). 
There was normal distribution of data when plotted as a histogram (fig 34) and a 
scatter plot showed data randomly distributed. The change of neurofiber rim showed 
a statistically significant result (F=3.99 t=-1.998 p=0.05) but the confidence limits 
were large (CI lower -2.244 to upper 0.34).  
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Figure 35 Histogram showing normal distribution of data in Hypertensive group comparing rim 
volume change against artery diameter reduction RE 
 
 
Pearson’s correlation was significant for LE for the Hypertensive group (p=0.05). 
There was normal distribution of data and a scatterplot showed the data to be 
randomly distributed. The rim volume change was statistically significant (F=4.072 
t=2.018 p=0.05) the confidence limits were large (CI lower -0.22 to upper 2.188). 
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6.2 Comparison MD, PSD and Artery Diameter 
 
 Comparison MD, PSD and Artery Diameter (F value, t value)( p value) 
Mean Deviation Pattern Standard Deviation 
RE LE RE LE 
Normal 0.014, 0.959 
(0.906) 
1.317, 0.804 
(0.26) 
7.481, -1.143 
(0.01) 
2.053,0.541 
(0.162) 
Glaucoma 2.713, -1.647 
(0.122) 
1.184, 1.088 
(0.295) 
2.689,1.64 
(0.123) 
1.097,0.56 
(0.313) 
OHT 0.049,0.221 
(0.827) 
0.297,0.543 
(0.591) 
1.008,-1.004 
(0.325) 
2,241, -1.497 
(0.147) 
Figure 36 Comparison MD,PSD and Artery Diameter 
Linear regression in the glaucoma group showed normal distribution both R&L eye. 
The RE in the glaucoma group r-value suggested a moderate correlation of 
diameter change being attributable to 16% of MD change. The LE r-value suggested 
only a small correlation of 7% MD change attributable to diameter change. 
 
Linear regression in the normal group showed a normal distribution both R&L eye. 
The RE in the normal group r-value suggested no correlation of artery diameter 
attributable to MD change. The LE in the normal group r-value suggested a small 
correlation of 20% MD attributable to diameter change. 
 
Linear regression in the OHT group showed normal distribution both R&L eye. The 
RE in the OHT group r-value showed no correlation of diameter change with MD. 
The LE r-value showed a small correlation of diameter change being attributable to 
11% of MD.  
 
Linear regression in the glaucoma group showed normal distribution both R&L eye. 
The RE in the glaucoma group, r-value, suggested a moderate correlation of 
diameter change being attributable to 16% of PSD change. The LE r-value showed 
a small correlation of 27% of PSD attributable to artery diameter change. 
 
Linear regression in the normal group showed normal distribution both R&L eye. 
The RE in the normal group r-value showed a significantly correlated moderate 
change of 45% PSD attributable to diameter change. The LE r-value showed a 
small correlation of 25% of PSD attributable to artery diameter change. 
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The linear regression in the OHT group showed normal distribution in both R&L eye. 
The RE in the OHT group showed a small correlation of diameter change being 
attributable to 20% of PSD change. The LE showed a small correlation of diameter 
change being attributable to 28% of PSD change. 
 
6.3 The Predictive Value of MD,PSD and Neuroretinal 
Rim volume on Artery Diameter 
 
A multiple linear regression was done to see if the neurofiber rim volume change 
combined with the PSD change and MD changes were able to predict the change in 
artery diameter. 
 
 Multiple Linear Regression Predictive Value of Neuroretinal rim volume, 
PSD and MD change to predict Artery Diameter Change  
RE (F=, adjusted r square,p=) LE (F=, adjusted r-square,p=) 
Normal 3.999,0.225,0.017 3.513,0.201,0.029 
Glaucoma 2,264,0,202,0.133 0.47, -0.119, 0.709 
OHT 1.709, 0.076, 0.193 1.922, 0.096, 0.154 
Table 24 Predictive Value of MD,PSD and NF rim volume on Artery Diameter 
The adjusted r-squared value was small in all three groups, making any predictive 
value meaningless. The reason for the adjusted r-squared value being so small is 
the small sample size. 
 
The significant correlation in the predictive value of change of PSD,MD and 
neurofiber rim volume in the normal group is a good indicator of the specificity of 
artery diameter change for correctly identifying normals. 
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6.4 Functional Analyses 
 
6.4.1 AGE 
The age distribution for each group was tested by Shapiro-Wilk for normality. Both 
the Glaucoma and Ocular hypertensive group were normally distributed (p>.05) but 
the normal group had a significant value (p=0.017), any statistics using age as a 
confounding parameter will use non-parametric tests. Visual inspection of the 
histogram and Q-Q plot showed normal distribution for all three groups and the 
skewness and kurtosis values are shown table 25. 
 
AGE Skewness (standard error) Kurtosis (standard error) 
Normal -0.813(0.421) -0.271(0.821) 
Glaucoma 0.107(0.564) -1.007(1.091) 
OHT -0.953(0.448) 2.051(0.872) 
Table 25 Values of Skewness and Kurtosis for Age Distribution 
6.4.2 IOP 
The group mean IOP for each of the examined groups at baseline and after one 
year is shown in Table 26. 
 
 Mean (SD) IOP (mmHg) 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal 16.6 (3.38) 16.3 (3.44) 16.0 (3.21) 15.2 (3.08) 
Glaucoma 19.1 (5.01) 18.8 (4.37) 17.2 (2.32) 16.0 (3.54) 
OHT 22.5 (3.31) 20.6 (2.83) 20.4 (3.39) 19.7 (3.37) 
Table 26 Group mean IOP for each of the examined groups 
The group mean IOP at baseline was significantly higher in the OHT group 
compared to the glaucoma group (RE 3.36mmHg greater p=0.01, LE 1.88 greater 
p=0.09) and normal group (RE 5.85mHg higher p=0.01, LE 4.37mmHg higher 
p=0.01), analysis of variance using repeated measures showed this difference to be 
significant for normal in both right and left eyes, but for the glaucoma group it was 
only significant in the right eye. In a paired t-test comparison between baseline and 
one year later there was no significant difference in normal right and left eyes (RE 
p=0.31, LE p=0.07), OHT patients had a small, but significant reduction right (RE 
2.87 p=0.01) but not in the left eye (LE p=0.17) With glaucoma, the right eye had no 
  82 
significant difference (RE p=0.08), but, the left eye was statistically reduced (LE 2.38 
p=0.03). 
6.4.3 Visual Field 
All visual fields were within the reliability criteria of <33% false positive and negative 
and <33% fixation losses. This is in agreement with the accepted normal for a 
reliable visual field. The visual field global indices of mean deviation (MD) and 
pattern standard deviation (PSD) were measured at baseline and one year later, 
shown in Table 27,28 
 
 Group Mean (SD) Mean Deviation (dB) 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal -0.05 (1.56) -0.27 (1.59) -0.27 (2.02) -0.45 (1.73) 
Glaucoma -0.50 (1.46) -3.08 (2.46) -0.69 (1.36) -3.86 (2.72) 
OHT -0.43 (1.67) -0.89 (1.92) -0.44 (1.95) -0.86 (2.15) 
Table 27 Global Mean Deviation Indices at baseline and after one year 
 Group Mean (SD) Pattern Standard Deviation (dB) 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal 1.93 (0.46) 1.96 (0.60) 2.05 (0.97) 1.89 (0.53) 
Glaucoma 3.09 (1.59) 4.75 (3.19) 2.79 (0.86) 4.79 (0.86) 
OHT 2.26 (0.67) 2.50 (1.45) 2.27 (0.82) 2.47 (1.95) 
Table 28 Global Visual Field PSD at baseline and one year later 
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Figure 37 LE MD Baseline and One Year Later 
 
Figure 38 RE PSD (dB) Baseline and One Year 
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Figure 39 LE PSD (dB) Baseline and One Year 
In comparison with paired t-test of mean deviation values both the OHT group and 
the normal group had no significant change between baseline and one year, OHT 
(RE 0.07 p=0.94, LE -0.12 p=0.91), normal (RE 0.97 p=0.34, LE 0.74 p=0.47). The 
glaucoma group did show a statistically significant worsening MD in the LE (RE 1.30 
p=0.21, LE 2.64 p=0.02). 
Using the t-test to compare PSD between baseline and one year there was no 
significant difference in all three groups, OHT (RE -0.30 p=0.98, LE 0.05 p=0.96), 
glaucoma (RE 1.71 p=0.11, LE -0.12 p=0.91) and normal (RE -0.89 p=0.38, LE 0.59 
p=0.56) 
Since there was no significant change in visual field indices between baseline and 
one year, all groups can be considered as stable and not progressing. The LE 
change in the MD of the LE for the glaucoma group did not have a corresponding 
change in PSD LE. 
6.4.5 Blood Pressure 
Table 28 illustrates blood pressure in terms of group mean diastolic and systolic 
pressures measured at baseline and one year later for each of the examined 
groups. 
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 Group Mean Diastolic and Systolic Pressures (mmHg) 
Baseline 1 Year After Baseline 
Diastolic Systolic Diastolic Systolic 
Normal 139.56 (17.31) 80.50 (6.75) 138.56 (17.05) 80.03 (5.72) 
Glaucoma 145.25 (24.07) 79.56 (6.24) 140.06 (19.39) 78.31 (3.89) 
OHT 135.93 (13.91) 82.48 (5.77) 139.19 (11.45) 81.44 (4.41) 
Table 29 Group mean Diastolic and Systolic Pressures baseline and one year later 
 
The mean group diastolic blood pressure at baseline was highest in the glaucoma 
group, but the differences between groups was not statistically significant. The 
mean systolic reading in the glaucoma group had become the lowest, but again at 
baseline between groups this was not significant. Using a paired t-test to assess 
significance between baseline and one year there was no significance in the normal 
group (diastolic 0.92 p=0.36, systolic 0.48 p=0.64). The OHT patients showed a 
significant increase in diastolic pressure but not systolic (diastolic -3.49 p=0.002, 
systolic 0.988 p=0.33). The glaucoma group had a significant reduction in diastolic 
but not systolic (diastolic 3.21 p=0.006, systolic 0.801 p=0.44). 
  
6.4.6 Ocular Perfusion Pressure 
 
Table 30 shows the group mean ocular perfusion pressure for each of the examined 
groups at baseline and one year later 
 
 Group Mean Ocular Perfusion Pressure (mmHg) 
Baseline 1 Year After Baseline 
RE LE RE LE 
Normal 63.39 (7.49) 63.67 (7.03) 63.36 (7.75) 64.15 (7.67) 
Glaucoma 63.10 (8.99) 63.40 (8.91) 62.46 (7.88) 63.65 (9.12) 
OHT 56.26 (8.40) 58.11 (7.90) 59.59 (6.40) 60.26 (6.20) 
Table 30 Group Mean Ocular perfusion pressure baseline and one year later 
In comparison between mean ocular perfusion pressure the OHT group had the 
lowest value this was statistically significant compared to the other two groups, 
glaucoma (RE -6.85mmHg p=0.01, LE -5.37mmHg p=0.03) normal (RE -7.03mmHg 
p=0.002, LE -5.56mmHg p=0.008) The normal group was not significantly different 
compared to glaucoma. Using t-test to compare baseline to one year, neither the 
normal nor glaucoma group were changed significantly, but, the OHT group did 
have a significant increase (RE 3.38 p=0.02, LE 2.6 p=0.02). 
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6.4.7 Corneal Thickness 
 
 Group Mean Central Corneal Thickness (μm) 
Baseline 1 Year Later 
RE LE RE LE 
Normal 579.34 (31.25) 580.66 (35.99) 578.28 (32.47) 581.09 (37.84) 
Glaucoma 572.94 (29.04) 568.87 (25.28) 579.5 (13.37) 568.5 (14.96) 
OHT 596.78 (65.88) 604.22 (84.69) 577.59 (33.52) 580.78 (35.56) 
Table 31 Group mean Central Corneal Thickness Baseline and One Year (µm) 
 
The cornea should not change in thickness without a pathological background, 
which was an exclusion criterion for entrance into this research. Therefore the 
central corneal thickness measurement can be simply treated as a baseline 
characteristic for each group. There was no significant difference between groups at 
baseline and no significant change in corneal thickness in any group between 
baseline and one year. 
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7.0 Discussion 
 
The research objective was to measure blood vessel diameter using the HRT. The 
interactive measurements tab in the software was used to measure blood vessel 
diameter to within 0.011mm. The results when comparing the separate 
hemispheres, superior and inferior, follow generally accepted values of vessel 
diameter (Wong, Shankar, et al. 2004; Lee, Kim, et al. 2014; Joos, Singleton, et al. 
1997). The artery diameter was larger when both hemispheres were combined. The 
initial reason for the increase in artery width was the fixed horizontal line that was 
used to consistently measure the same position in the artery between two visits. 
This line bisected the artery at an angle that was greater than the perpendicular and 
therefore the value was naturally greater. This increase in diameter was then 
mathematically inflated when entering the value into the correction equation for 
vessel diameter. The important value is the diameter change over time; as a 
consequence the average diameter being larger was of no relevance to statistical 
outcomes. This variation of bisection of blood vessels being perpendicular for some 
vessels but almost parallel for others explains the much larger standard deviation 
compared to other research. But, the trend for glaucoma arteries to be smaller in 
diameter than normal arteries held (Lee, Kim, et al. 2014); this decrease in diameter 
is thought to be a predictor for glaucoma onset. 
The basis of glaucoma diagnosis is separating structural and functional changes 
relative to the normal eye. The aim of the research was to evaluate whether a 
correlation exists between functional change defined by the visual field status and 
retinal vessel diameter change with a normal group acting as the control, the 
glaucoma group being a known disease variable and the OHT group acting as an 
“at risk’ population under observation.  
 
The IOP diurnal variation has been compared between right and left eyes (Liu, Sit, 
et al. 2005) and not found to be different. This agrees with these results in both the 
normal and glaucoma group, which would be expected in a stable population. The 
OHT group did show reduction in IOP in the right eye, but the standard deviation 
was relatively high at 3.39mmHg so this finding could be a statistical outlier rather 
one of clinical significance. The same outlier argument could be used for the 
reduction in IOP left eye since again the standard deviation of the group was 
relatively high at 3.54mmHg. The majority of volunteers were statistically similar in 
measurement of IOP between baseline and one year, as a group statistic any one 
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individual would need to change by a large amount to show up as significant against 
a stable majority. 
 
The difference between right and left eye vessel diameters for the 75 volunteers at 
baseline was compared. There was no difference in any group, and this would 
agree with the revised formula research of (Knudtson, Lee, et al. 2003) who did not 
differentiate between right and left eye vessel diameters when using their 
researching their central retinal vessel equivalent calculation. The method of retinal 
vessel calculation using the revised formulas was central to this research, and post 
2003, was overwhelmingly the calculation of choice among more experienced 
researchers (Wong 2004; Kawasaki, Wang, et al. 2013). The lack of significant 
differences between right and left eyes for vessel diameter reduces the possibility of 
the left eye being influenced by its proximity to the heart and a higher systolic blood 
pressure. 
 
The central retinal artery/vein equivalent formula is now an accepted standard in 
research, but there is no accepted framework for how to measure vessel diameters 
using manual or automated methods. Nor is there a framework for the assessment 
of inferior or superior vessel diameters. This research measured these parameters 
as separate values, and compared them directly to other known indices of 
glaucomatous change i.e. IOP and visual field global indices. Uniquely, this 
research took advantage of the interactive tab on the HRT machine software to 
measure blood vessels using the movable cursor over a fixed retinal image without 
need for magnification correction or exporting an image to a separate computer 
program for analysis. 
 
Previously with manual measurement of blood vessels was carried out by taking the 
retinal image and projecting onto a wall, then physically measuring at a known point 
followed by a mathematical calculation accounting for the magnification, and 
converting the value into millimetres. The most difficult part in this task was 
measuring at exactly the same point one year later. The HRT has inbuilt software to 
align the optic disc, allowing calculation of neuroretinal rim volume, and attributing 
change to sectors on the disc which are then used in its progression software to 
deduce if there has been a statistical change suggestive of glaucoma. This means 
that the optic disc, and subsequently the blood vessels are always in the same 
position and the X, Y placement values determined for each measurement at 
baseline can be returned to at any point thereafter. One of the difficulties discussed 
in other research about taking manual measurements was the determination of 
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blood vessel edge (Rassam, Patel, et al. 1994). This was also a confounding 
variable whilst using the HRT. It was alleviated somewhat by the interactive tab 
having two additional line graphs showing a 2D topography of the vertical and 
horizontal retina. When taking the measurements these were utilised to determine 
the beginning of the vessel edge, the sudden change in height visible on contour 
line set against a relatively flat retinal background. There was generally a slight dip 
in traveling over the vessel due to the lumen but the edges were identified because 
of their height in comparison to surrounding contours. Where this identification was 
difficult, measurements were avoided in order to reduce repeatability errors in the 
data. Because there is no option to magnify the image, then small diameter vessels 
<0.012mm were not measured because edges could not be identified. The 
identification of blood vessels as either artery or vein was sometimes unknown and 
these vessels were also not included in data collection. This is an unfortunate 
consequence, since it is the smaller diameter arteries that are thought to be affected 
first in the glaucoma disease process (Sun, Wang, et al. 2009), and therefore this 
data was lost to analysis. One way to improve this data collection would be to 
increase the scanning accuracy of the confocal laser and add a magnification option 
to the interactive tab, but, this is a difficult option because the confocal system has a 
physical limit of the moving mirror and aperture setup (figure 11) so the 
improvement is directed towards the machine hardware as opposed to software 
interpretation of already gathered data. The measurement of blood vessels has a 
learning curve for the user, and a specific weakness in this research was the 
absence of any consistency check of diameter data collected. For each volunteer 
there was no anonymity or masking of patient grouping, but each data collection 
was carried out immediately after scanning without reference to other volunteers or 
previous measurements for that individual. A Bland-Altman plot was done on one 
group of 10 participants from both the normal and glaucoma volunteers. This 
involved a second measurement done on the baseline data and compared to the 
original data to determine continuity of measurement. The plot, kurtosis and 
skewness showed a normal distribution and any differences to be within accepted 
values. Although this is not ideal for collection of data the aim of this research was 
to determine if this vessel diameter variable could be determined by the HRT and 
therefore used as a reliable criteria for glaucoma detection in a high street 
optometric practice. The research data collection did not have the statistical 
robustness of a random control trial, but instead was based in the real world 
scenario of a high street optometrist screening for glaucoma.  
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The difficulty in assessing change of blood vessel diameter in the group of 75 
volunteers is that the disease pattern is often stable and therefore no change would 
be expected. The general expected baseline results did concur with current 
research but any change in vessel diameter may have been masked and 
consequently did not show up in the statistical analysis. The general data did show 
a decrease in the left eye superior artery diameter, but this was not corroborated by 
a change in left eye the MD or PSD value in the visual field, and so was probably an 
outlying statistic. The OHT group did show a reduction in artery diameter for both 
inferior and superior in the left eye, but this did not manifest as a change in visual 
field and neither did it manifest as a reduction in neuroretinal rim volume. When the 
data from the four suspect volunteers were separated from the stable data the 
typical glaucomatous change in visual field was noted in both MD and PSD with a 
much greater change in the left eye and this would explain its statistical presence 
even combined with the stable data. All of the glaucoma suspects developed a 
greater visual field defect in the superior visual field, and this correlated well with the 
reduced volume in inferior neuroretinal rim. When comparing the artery diameter, 
both right and left superior and inferior had diameters had reduced, but the inferior 
diameter had reduced by a greater amount in comparison to superior diameter and 
to a greater extent in the left eye compared to right eye which is consistent with the 
visual field outcome and also current research findings which suggest that artery 
diameter change being is linked with glaucoma. The vein diameter also decreased 
between baseline and one year but not by the same degree as artery diameter. The 
difficulty posed when measuring blood vessel diameter would suggest that the 
current viewpoint of changes in vein diameter not being significant is probably 
correct. 
 
Three of the OHT group and one in the normal group were suspect for conversion to 
glaucoma and have subsequently been referred with all relevant data to be 
assessed by an ophthalmologist. When this group data was separated out and the 
same t-test and one-way ANOVA performed there was no significant change 
between baseline and one year. It is assumed that the reason for a result of no 
statistical significance is due to the very small sample size. It was noted that when 
simply observing the results the IOP and ocular perfusion pressure were almost 
static but the predicted results of visual field indices (MD & PSD), optic disc rim 
volume (total, superior & inferior), optic disc rim area, and artery diameter (superior 
and inferior) all changed as expected for a positive glaucomatous diagnosis. This 
would suggest a larger sample size would allow a statistical significance to prove a 
clinical observation. 
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Blood vessel diameter is known to reduce with age by approximately 4.8μm for 
CRAE and 4.1μm for CRVE every increase of 10 years (Leung, Wang, et al. 2003). 
This value was significantly less than the diameter change found in the OHT group 
over only one year. This natural decrease in diameter for both artery diameter and 
vein diameter is a useful known variable for assessing abnormality over time in 
suspect groups. 
If blood vessel diameter is considered as a risk factor alongside all other variables 
then it may be advisable to bracket the diameters into different groups, allowing for 
a range of diameters within a set range in any one group. This would highlight the 
importance of an individual moving between groups. The Blue Mountains Eye Study 
did exactly this when assessing risk of glaucoma over ten years for a standard 
deviation decrease in artery diameter giving an odds ratio of 1.77 (95% CI 1.11-
2.78). This odds ratio increased as incidence of glaucoma persisted with IOP less 
than 20mmHg (Kawasaki, Wang, et al. 2013). They divided up their patient base 
into four groups of artery diameters; this grouping would allow a higher sensitivity 
but a lower specificity. In our research the individual measurements allow a higher 
specificity but the repeatability of the measurements need to be high.  The manual 
aspect of vessel measurement would probably be more suited to placing the patient 
in a certain diameter group on baseline measurement allowing this variable to act 
more as a risk factor for glaucoma onset or progression as opposed to an absolute 
change defining the beginning of glaucoma.  
 
There are two questions to consider when accepting the reduction of artery diameter 
reported by this research, with regards to glaucoma onset and whether it could be 
considered as an important variable in glaucoma progression. 
1) Why does the artery change in diameter? 
2) Does the artery change before ganglion cell death occurs? 
Blood vessels are composed of two interacting cell types. Endothelial cells form the 
inner lining of the vessel wall and pericytes envelope the surface of the vascular 
tube. Pericytes are the supporting cells of the microvasculature. Elevated BP 
produces changes in the pericytes in the retinal capillary walls (Wallow, Bindley, et 
al. 1993) Pericytes are functionally significant; when a vessel loses a pericyte they 
become haemorrhagic and hyperdilated (Bergers & Song 2005). 
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Figure 40 Pericyte Function on Blood Vessels (Google images) 
http://www.nature.com/neuro/journal/v14/n11/images/nn.2946-F4.jpg 
 
It has been shown that oxygen levels regulate pericyte contraction and that pericyte 
density is dependent on blood pressure levels with the highest density of pericytes 
found in the retina, and analysis of structure in diabetic retinopathy showing micro 
aneurysms coincident with pericyte dropout (Bergers & Song 2005). This pericyte 
susceptibility to BP and IOP and their role in vascular stability may mean they are 
the initiating factor in artery diameter reduction and subsequently retinal ganglion 
cell death. 
 
The initiating factor in dysregulation of ocular blood flow is coincident with 
endothelium-1 (ET-1)(Grieshaber, Mozaffarieh, et al. 2007). This increased level of 
ET-1 lead to a reduction in blood flow in both the choroid and the optic nerve head. 
There is estimated to be four times as many pericytes in the retina compared to a 
similar area in the brain, which is the only other vascular bed with equivalent 
properties to that of the retina. This increased density, is also known to be combined 
with a turnover rate, which is slower than any other vascular bed. ET-1 is a very 
potent vasoconstrictor.  ET-1 and nitric oxide are important mediators of cellular 
signalling within the retinal microvasculature, ET-1 has been shown to cause retinal 
pericyte contraction (Chakravarthy 1999).  
 
The retinal blood vessels are known to lie in the nerve and ganglion cell layer from 
examination of OCT scans of the 3D retina topography (Zhu, Tong, et al. 2014). The 
weight of evidence is building for the role of vascular dysregulation in glaucoma with 
known factors such as poor auto regulation in glaucoma sufferers (Leske 2009), 
migraine associated with glaucoma (Phelps & Corbett 1985) and blood pressure 
(Zhao, Cho, et al. 2014). The suggestion of Topouzis et al that BP alone has been 
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shown to effect optic disc cupping is suggestive of ganglion cell death (Topouzis, 
Coleman, et al. 2006). Furthermore, the finding that ACE inhibitors have an 
inhibitory effect on glaucoma progression by controlling BP by dilating blood vessels 
(Hirooka, Baba, et al. 2006) adds to the weight of there being significant vascular 
factors involved in the development and progression of  glaucoma. 
 
Up to 50% of the ganglion cells need to die to give a reliable glaucomatous field loss 
(Kerrigan–Baumrind, Quigley, et al. 2000; Katz, Gilbert, et al. 1997), it is difficult to 
ascertain at what point narrow arteries catalyse or initiate ganglion cell death. The 
determination of when glaucoma starts to develop point is still fraught with 
difficulties, and although vessel diameter is an increasingly important variable, the 
interpretation of diameter as a weighting factor when set alongside well researched 
parameters needs careful consideration. 
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8.0 Implications for Optometry Practice  
When considering Glaucoma as a disease, the raised IOP in congenital, angle 
closure and secondary glaucoma’s demonstrate that IOP can be the sole factor 
causing the condition. Conversely, the findings of glaucomatous cupping, loss of 
neurfibers at the optic disc and repeatable defects in the visual field show glaucoma 
in patients who have normal IOP. These two, polar opposite IOP cardinal signs, 
suggest there are other significant weighting factors in the transformation of a 
healthy eye to glaucoma. 
 
In the early diagnosis of glaucoma, optometrists in the UK rely on the triad of IOP, 
visual field and optic disc assessment. The measurement of IOP is variable, 
because of the diurnal factor, corneal thickness, instrument used and glaucoma as a 
condition makes the IOP more variable between troughs and peaks. The field exam 
is variable, not only because of subjective considerations, but also because the 
redundancy in retinal ganglion cells does not translate into consistent visual field 
defects. The final part, in this longstanding triad of glaucoma diagnosis, is optic disc 
assessment. The optometrist is attempting to describe a 3D object in a 2D picture, 
adding the important detail of change, in a 3mm2 circle containing 1.2 million nerves, 
to finally come to a conclusion of normality, in the 3 minutes allocated to fundoscopy 
during an eye exam. 
 
Measurement of retinal arteries would add an objective, independent factor to aid 
diagnosis in glaucoma in its many permutations. 
 
Glaucoma appears to follow a pattern of blood vessel diameter change, followed by 
neuroretinal rim loss leading to visual field loss. All other factors act as a catalyst for 
each of these sequenced events. 
With further software development it may be possible to automate measurement of 
blood vessel diameters and calculate the percentage change considered to be 
outside of normal limits with respect to a large robust normally distributed 
population. With an increasing database then the predictive power of artery 
diameter change would become a dependable factor in glaucoma diagnosis. 
  
The primary function of the HRT is a machine for assessing neuroretinal rim volume 
and determining change over time. The added value of its ability to assess blood 
vessel diameter, would allow a high street optometrist to add this as a weighting 
factor in their glaucoma decision. 
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But, the manual aspect of fine repeatable measurements, make this a time 
consuming task, with no definite diagnosis of glaucoma or normality at the end. Until 
larger scale studies are carried out to determine the clinical value of blood vessel 
diameter measurement in glaucoma diagnosis, its use is limited. 
 
8.1 Future Work 
The most important development for this work would be expansion it to a much 
larger clinical population of normal, and then comparison a larger range of glaucoma 
patients, stratified precisely for degree of glaucoma severity. A randomised control 
study would need to confirm the repeatability, of vessel diameter measurements. 
 
The HRT has inbuilt software for predicting glaucoma or the probability of 
glaucomatous damage. This research did not utilise any available data from these 
programs. The HRT software has already been shown in research to be predictive 
of glaucoma. Because the change in artery diameter is also considered a pre-
perimetric change then using the progressor software and following over an 
extended period of time, has the potential to corroborate early diameter narrowing 
with HRT values and visual field loss. 
 
With the increasing availability of the spectral-domain optical coherence tomography 
(SD-OCT) and its acceptance as a normal purchase for a high street optometry 
practice, the extension of the scan to volume data collection of retinal artery and 
vein diameters may become a valuable resource of general health indicators for 
cardiology, general practice and ophthalmology. A recent study using SD-OCT 
technology showed reliable, repeat measurements of vascular structure (Zhu, Tong, 
et al. 2014), and this will only increase in accuracy with improving scan speed, 
depth and measurable anatomical change. The automatic identification of veins and 
arteries would allow for computerised diameter measurement, this would allow 
utilisation of this additional criteria to be added as a further weighting factor in early 
glaucoma detection.  
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10.0 Appendix 
 
10.1  Volunteer Information Sheet 
 
Researchers, School and subject area responsible   
Principal Investigator: Mr Colum Rooney, 5 Ballynahinch Street, Hillsborough, 
Northern Ireland 
 
Project Supervisor: Dr Robert Cubbidge, Optometry, Life and Health Sciences, 
Vision Sciences, Aston University 
 
Project Title The influence of blood vessel diameter on glaucoma 
progression 
 
Invitation 
You are being invited to take part in a research study. Before you agree it is 
important for you to understand why the research is being carried out and what it will 
involve. Please take time to read the following information carefully. 
 
What is the purpose of this study? 
When an optometrist looks into the back of your eye they can see the small blood 
vessels which supply your retina. The purpose of this investigation is to assess the 
retinal blood vessels in order to determine whether they change in size with 
glaucoma. 
 
There are no personal benefits to participation in this research and all of the tests 
carried are available if necessary in your normal eye examination. 
 
If blood vessels are found to alter in size in glaucoma, this finding may become an 
aid in the diagnosis of glaucoma.   
 
Why have I been chosen? 
You have been asked to participate in this study because you fall into one of three 
pre-determined groups; 
 1/ diagnosed glaucoma 2/ the pressure of the liquid inside your eye is higher than in 
the normal population but is not damaging your eye 3/ you have no detectable risk 
of glaucoma. 
 
The study aims to recruit 120 subjects. 
 
What will happen to me if I take part? 
If you agree to participate, you will be asked to attend the practice in Hillsborough 
on four separate occasions. The first visit should take about 30 minutes to complete 
and is an extended eye examination; this will involve the normal eye examination 
plus a measurement of your blood pressure. An image of the back of your eye will 
then be taken using an instrument called a Heidelberg Retinal Tomograph. You will 
be asked to place your chin on a rest and look at a steady flashing red light. The 
image takes a few seconds to acquire and you will see a bright red light from a low 
powered laser. This imaging procedure is commonly used in hospital eye clinics and 
is known to be safe. 
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There are two additional measurements not normally taken in an optometric practice, 
these are, corneal thickness (the clear window of your eye) and gonioscopy. A 
single drop of local anaesthetic will be placed in your eyes, the effects of which will 
wear off after about 30 minutes. Two procedures will be performed on each eye. In 
the first procedure, a contact lens type instrument called a gonioscope placed on 
your eye to observe the structures inside your eye where liquid normally drains into 
the blood stream. Secondly, a plastic pen-like instrument will lightly touch the front 
surface of your eye (the cornea) to measure its thickness.  
 
The second visit will take place one week later when you will be asked to repeat the 
visual field test completed during the first visit, this is a peripheral field exam where 
you click a button when you see lights at the corner of your vision, this  will only take 
ten minutes and does not require any anaesthetic drops. 
 
After one year you will be recalled for a repeat of the first visit, and your fourth and 
final visit will, once again, repeat the visual field measurement. 
 
Should any of the tests reveal an eye problem, you will be referred to an 
ophthalmologist.  
 
Should the blood pressure measurement show a high reading, you will be referred 
to your GP for further investigation.  
 
Are there any potential risks in taking part in the study? 
There is a very small risk that the topical anaesthetic Benoxinate Hydrochloride may 
cause a toxic reaction which causes corneal inflammation. If this occurs, your vision 
will be monitored closely and if necessary you will be referred urgently to an 
ophthalmologist. 
 
The gonioscope and instrument which measures corneal thickness could cause an 
abrasion to the corneal surface. This does not occur often and in most cases, the 
regenerative ability of the cornea leads to healing within about an hour. Your eyes 
will be checked for abrasion after these procedures have been carried out and if it 
an abrasion is found to be severe, which occurs very rarely, you will be referred to 
an ophthalmologist for treatment. 
 
Do I have to take part? 
No, you do not have to participate and you are also free to withdraw from the study 
at any time after agreeing to take part without any giving a reason. Your normal eye 
care will not be affected by not participating.  
 
Expenses and payments? 
No expenses or payments can be offered for participating in this research.  
 
Will my taking part be kept confidential? 
In accordance with the Data Protection Act, Mr Colum Rooney will be the only 
investigator who has access to your name. Any database used for analysis of the 
results will not contain your name. Your name will be replaced by an identification 
number which will only be known by Mr Rooney.  All data used for analysis will be 
encrypted electronically and stored in a secure location. 
 
You will not be able to be identified in any future publication of results. 
 
What will happen to the results of the research study? 
The results from this research may be published in a thesis and peer reviewed 
journal. You will not be identifiable in any of these publications. 
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Who is organising and funding the research? 
This project and purchase of additional equipment is fully funded by Colum Rooney. 
 
 
Who has reviewed the study? 
The research has been approved by the Audiology and Optometry Research Ethics 
Committee (AROC) at Aston University 
 
Who do I contact if something goes wrong, or I need further information? 
In the first instance, you should contact Mr Colum Rooney, 5 Ballynahinch Street, 
Hillsborough, BT26 6AW, (028) 9268 8881 
 
Who do I contact if I wish to make a complaint about the way in which the 
research is conducted? 
If you have any concerns about the way in which the study has been conducted 
then you should contact the Audiology and Optometry Research Ethics Committee 
(AROC) at Aston University, l.n.davies@aston.ac.uk  0121 204 4152 
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10.2  Volunteer Consent Form 
       
 
                                                      
  
 
Personal Identif ication Number: 
______________________ 
 
CONSENT FORM 
Title of Study :The influence of blood vessel diameter on glaucoma progression 
 
Research Venue: 5 Ballynahinch Street, Hillsborough, Northern Ireland  
 
Investigators’ names: Mr. Colum Rooney, 5 Ballynahinch Street, Hillsborough, 
Northern Ireland 
   Dr. R.Cubbidge, School of Life & Health Sciences, Aston University 
 
 Please t ick boxes as appropriate 
 
1. I confirm that I have read and understood the information sheet dated  !
 (version ............) for the above study. 
 
2.   I have had the opportunity to ask questions about the study and I 
      was given a minimum of 24hrs to make a decision on participation.                     ! 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, 
 without giving any reason and without my legal rights being affected.                       ! 
5. I agree to take part in the above study.                     ! 
___________________ ____________________ 
Full name of Research Participant Date (dd/mm/yyyy) Signature 
 
_________________________ ____________________ 
Full name of Researcher Date (dd/mm/yyyy) Signature 
Aston Triangle 
Birmingham, B4 7ET, UK 
Phone: +44 (0) 121 2043853 
Fax: +44 (0) 121 2043892 
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10.3  Audiology & Optometry Ethics Approval 
 
 
AUDIOLOGY & OPTOMETRY ETHICS FORM 
 
All parts of the Ethics Application must be written concisely using terminology that would be 
understandable to an educated lay person on an ethics committee.   
 
Title: The influence of blood vessel diameter on glaucoma progression  
 
Principal Investigator: Mr Colum Rooney 
Contact Details: 5 Ballynahinch Street, Hillsborough, Northern Ireland 
 
Other Staff / Students involved:  Dr Robert Cubbidge, Optometry, School of Life & Health 
Sciences, Aston University, Birmingham B4 7ET, r.p.cubbidge@aston.ac.uk 
 
A. PROJECT OBJECTIVES / BACKGROUND  
A1.  What are the primary research questions / objective? 
Purpose and Justification: 
The purpose of this study is to correlate either progression in glaucoma, or conversion to 
glaucoma, against blood vessel diameter changes measured using the Heidelberg Retinal 
Tomograph 3(HRT). We hypothesise that the diameter of retinal blood vessels is altered in 
glaucoma.   
 
Early diagnosis of glaucoma is critical to prevent permanent structural damage and 
irreversible vision loss. Currently, the diagnosis of glaucoma is made via a triad of tests; 
optic disc assessment, intra-ocular pressure (IOP) and visual field examination. These tests 
are looking for typical glaucoma traits in the form of ganglion cell loss on the optic disc, 
raised IOP with the potential to cause harm and a pattern of visual field loss typical of 
glaucoma. There are two other parameters not normally taken in a high street optometry 
practice aiding glaucoma diagnosis, central corneal thickness (CCT) and ocular perfusion 
pressure (OPP). 
 
OPP is defined as the difference between arterial and venous pressure, in the eye, venous 
pressure is equal to, or slightly greater than IOP. OPP can therefore be defined as the 
difference between blood pressure (BP) and IOP. OPP can be further broken down to 
diastolic perfusion pressure and systolic perfusion pressure. These values are gaining 
increasing significance in glaucoma literature, helping to explain why lowering of IOP past 
the assigned target level does not slow glaucoma progression. In the Early Manifest 
Glaucoma Trial low systolic perfusion pressure, low systolic blood pressure and 
cardiovascular disease were predictors of glaucoma.  
 
Significant reductions in flow velocities, and increases in resistance indices, of blood vessels 
in both primary open angle glaucoma, and normal tension glaucoma, in comparison to 
normal control subjects have been demonstrated using scanning laser Doppler flowmetry.  
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By making an assessment of visual field status, vascular status and retinal blood vessel 
diameter, this research aims to determine if there is a retinal vascular element that is 
measureable in a high street optometry practice, in the hope that it will further aid glaucoma 
diagnosis. Scanning laser tomography will be used to quantify blood vessel diameter change 
longitudinally and cross-sectionally in addition to estimation of ocular perfusion pressure. 
 
 
 
A2.  Where will the study take place? 
Practice based: 5 Ballynahinch Street, Hillsborough, Northern Ireland 
 
 
A3.  Describe the statistical methods and/or other relevant methodological approaches to be used in 
the analysis of the results (e.g. methods of masking / randomization) 
The protocol will be randomised between volunteers in order to minimise any order effects.  
 
A4.  List the clinical techniques to be conducted on patients as part of the study and indicate whether 
they fall within the scope of normal professional practice of the individual to perform them 
Each volunteer will be required to attend for four times. The patient will be examined with an 
extended eye  iexamination on their first visit involving prescription determination, 
keratometer readings, IOP with Goldmann, stereoscopic fundus examination using a volk 
lens, gonioscopy to evaluate the anterior angle, slit-lamp exam on anterior eye, central 
corneal thickness measurement using an ultrasound pachymeter, blood pressure 
measurement, scanning laser retinal tomography of the optic nerve head using the HRT and 
finally a full threshold visual field examination. At the second visit which will take place one 
week after the first visit, the visual field examination will be repeated in order to reduce the 
perimetric learning effect.  
 
Visits 3 and 4 are a repeat of visits 1 and 2 and will take place one year after they have 
attended for the initial visits. 
 
B. RESEARCH PARTICIPANTS 
B1.  How many participants will be recruited? Please provide justification (power analysis software 
available from http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/) 
Using the diameter of artery and vein measurements reported in the Blue Mountains Eye 
Study, and knowing that a two tailed parametric test will be performed on the data, allows 
the GPower program to estimate the sample set that will be required. This estimate varies 
between 7-44 depending on whether vein or artery diameter is used. Based on this 
estimation forty volunteers per group will be recruited. In total 120 volunteers will be 
recruited for this research.  
 
B2.  What restrictions will there be on participation (age, gender, language comprehension etc)? 
Three patient groups will be recruited (40 volunteers in each group). The research participants will 
be between the ages of 30-70 since this is the group most prone to glaucoma. 
The research will involve a selection of patients from a normal, high street optometrists. 
These will be selected, and placed into three categories of patients; 
-1/ Normal: defined as a patient with no glaucomatous visual field loss, no optic disc 
changes suggestive of glaucoma and IOP<21mmHg 
-2/ Ocular Hypertensive: defined as a patient with no glaucomatous visual field loss, no optic 
disc changes suggestive of glaucoma and an IOP>21mmHg 
-3/ Glaucoma: defined as a patient diagnosed with glaucoma by an ophthalmologist and 
currently under review by them. 
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Because of the NICE directive, and guidelines from the College of Optometrists all 
hypertensive patients will have been referred and discharged by the hospital, or, are 
presently waiting to be seen. 
Ethnicity may be a complicating factor in blood vessel diameter change, research has 
suggested different progression rates of glaucoma despite similar IOP with the suggested 
explanation relating to its vascular etiology. The demographics of N.Ireland, and in particular 
the patient sample area will heavily skew the ethnicity towards Caucasian. This will help 
reduce the variables for statistical analysis.   
 
EXCLUSION CRITERIA 
I intend to limit the glaucoma group to only those being treated with Latanoprost (Xalatan, a 
prostaglandin analogue) This will remove the potential complicating factor of beta-blockers 
as a treating agent for glaucoma and its potential for effecting blood vessel diameter 
 
I will not include any participants who have a significant general health history, significant 
ocular history or a notable mental health history so as to attempt to normalise variables 
between the three research groups.  
 
General Exclusion criteria will include 
• Refractive correction greater than +/- 4.00DS and 2.00 DC 
• Medication known to influence the visual field 
 
• Diabetic patients 
 
• Patients with significant lens opacity 
 
• Closed angle glaucoma and volunteers who’s anterior angles are at risk of closure 
 
Specific Inclusion criteria relating to the glaucoma group 
• Glaucoma will be treated with Latanoprost (Xalatan, a prostaglandin analogue) This 
will remove the potential complicating factor of beta-blockers as a treating agent for 
glaucoma and its potential for effecting blood vessel diameter 
 
The NICE guidelines will be followed for any patient found to become glaucoma suspect in 
either the normal or ocular hypertensive group, and referral to an ophthalmologist arranged; 
whilst any progression in the glaucoma group will be noted and a copy sent to their treating 
ophthalmologist for consideration in their complete care regime. 
B3.  How will potential research participants in the study be (i) identified, (ii) approached and (iii) 
recruited?  If research participants will be recruited via advertisement then attach a copy of the 
advertisement in the appendix of the ethics report. 
The volunteers will be recruited from the patients attending Mr Colum Rooney’s Optometry 
practice. 
 
B4.  Will the participants be from any of the following groups? Tick as appropriate and justify any 
affirmative answers. 
Children under 16:   
Adults with learning disabilities:   
Adults who are unconscious or very severely ill:  
Adults who have a terminal illness:  
Adults in emergency situations:  
Adults with mental illness (particularly if detained under Mental Health Legislation):  
Adults suffering from dementia:  
Prisoners:  
Young Offenders:  
Healthy volunteers:  
Those who could be considered to have a particularly dependent relationship 
with the investigator, e.g. those in care homes, audiology students:  
Other vulnerable groups:  
 
Justification for healthy volunteers is outlined above in section B2. 
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B5.  What is the expected total duration of participation in the study for each participant? 
12 months 
 
B6.  Will the activity of the volunteer be restricted in any way either before or after the procedure (e.g. 
diet or ability to drive)? If so then give details. 
no 
 
B7.  What is the potential for pain, discomfort, distress, inconvenience or changes to life-style for 
research participants during and after the study? 
No additional precautions are required before or after the visit other than advice following the 
instillation of benoxinate hydrochloride local anaesthetic drops.  
 
B8.  What levels of risk are involved with participation and how will they be minimized? 
Hazards 
The participant may become distressed by one of the procedures, or during the study we 
may find a new eye condition. 
 
There is a very small risk that the topical anaesthetic Benoxinate Hydrochloride may cause a 
toxic reaction which causes corneal inflammation. If this occurs vision may become blurry 
and gritty pain may follow the effect of the anaesthetic wearing off. Patients who exhibit a 
toxic reaction to the anaesthetic will be monitored closely and if necessary referred urgently 
to an ophthalmologist. 
 
The gonioscope and instrument which measures corneal thickness could cause an abrasion 
to the corneal surface. This does not occur often and in most cases, the regenerative ability 
of the cornea leads to healing within about an hour. Slit lamp examination of the cornea after 
the procedures will check for abrasion and if found to be severe, which occurs very rarely, 
the volunteer will be referred to an ophthalmologist for treatment. 
Gonioscopy and measurement of corneal thickness involves direct contact of probe with the 
surface of the cornea. If the intraocular pressure is found to be above 21 mmHg through the 
screening process, then the volunteer will undergo further investigations in accordance with 
the NICE guidelines for referral of glaucoma and ocular hypertension to determine the 
presence of either condition. If necessary, the optometrist referral pathway for these 
conditions will be followed. 
 
 
 
B9.  What is the potential for benefit for research participants? 
No direct benefit.  
 
B10.  If your research involves individual or group interviews/questionnaires, what topics or issues 
might be sensitive, embarrassing or upsetting?  Is it possible that criminal or other disclosures requiring 
action could take place during the study? 
N/A 
 
B11.  How will participants be de-briefed after the study? [See separate guidance notes on designing a 
De-briefing Sheet] 
Volunteers will be de-briefed verbally. Information sheets supplied to volunteers express the 
opportunity for participants to request copies of any associated published material 
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B12.  Describe any arrangement that have been made for indemnity insurance, if you have reason to 
think it is not already covered by the University's policy. [NOTE: We have been advised by the Risk & 
Insurance officer that research on Aston campus, or undertaken by Aston OD students, is covered by 
the University's professional indemnity policy, currently provided by Zurich Municipal Insurance with a 
£10 million limit. ]  
Covered by Aston University policy 
 
 
 
C. CONSENT 
C1.  Will a signed record of informed consent be obtained from the research participants?  If consent is 
not to be obtained, please explain why not.  
Yes 
C2.  Who will take consent and how it will be done?  
Prospective volunteers will be supplied with information sheet. An investigator and 
prospective volunteer will convene at least 24 hours after to discuss any issues raised by the 
prospective volunteer before signing of consent form by both investigator and volunteer. 
 
The participant will be informed before they enter the study both in writing and orally that 
they may leave the study at any time. If we discover a new eye condition we will ensure that 
they receive the correct advice and referral, consistent with the statutory regulatory 
framework of optometric practice. 
 
 
C3.  How long will the participant have to decide whether to take part in the research? Justify your 
answer. 
24 hours. Volunteers will be supplied with an information sheet. This is the minimum period of time 
recognized by the NHS National Research Ethics Service guidance for participation to qualify as 
informed consent.     
 
C4.  What arrangements are in place to ensure participants receive any information that becomes 
available during the course of the research that may be relevant to their continued participation? 
If we discover a new eye condition we will ensure that they receive the correct advice and 
referral, consistent with the statutory regulatory framework of optometric practice 
 
C5.  Will individual research participants receive any payments/reimbursements or any other incentives 
or benefits for taking part in this research?  If so, then indicate how much and on what basis this has 
been decided? 
No 
 
C6. How will the results of research be made available to research participants and communities from 
which they are drawn?  
Information sheets supplied to volunteers express the opportunity for participants to request 
copies of any associated published material 
 
D.  DATA PROTECTION 
D1.  Will the research involve any of the following activities? Delete as appropriate and justify any 
affirmative answers.  
Examination of medical records by those outside the NHS, or within the NHS 
by those who would not normally have access:  
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Electronic transfer of data by e-mail:  
Sharing of data with other organizations:  
Use of personal addresses, postcodes, faxes, emails or telephone numbers:  
Publication of direct quotations from respondents:  
Publication of data that might allow identification of individuals:  
Use of audio/visual recording devices:  
 
 
D2.  Will data be stored in any of the following ways? Delete as appropriate and justify any affirmative 
answers.  
Manual files:  
Home or other computers:  
University computers:  
 
Data will be accessible only from local computers. Access to data is password protected. 
 
D3. What measures have been put in place to ensure confidentiality of personal data? Give details of 
whether any encryption or other anonymisation procedures will be used, and at what stage.  
All volunteers will be assigned a personal identification number. Only the personal 
identification number will be used for storing data. 
D4. If the data are not anonymised, where will the analysis of the data from the study take place and by 
whom will it be undertaken? 
N/A 
D5. Other than the study staff, who will have access to the data generated by the study? 
None 
D6. Who will have control of, and act as the custodian for, the data generated by the study? 
Mr Colum Rooney  
 
D7. For how long will data from the study be stored [minimum 5 years]? Give details of where and how 
the data will be stored. 
Data will be stored for at least 7 years. Data will be stored on computer machines. Rooms 
are locked and require key access. Access to data on machines will be password protected. 
 
E.  GENERAL ETHICAL CONSIDERATIONS 
E1.  What do you consider to be the main ethical issues or problems that may arise with the proposed 
study, and what steps will be taken to address these?  
The primary ethical considerations relate to hazards associated with the investigative 
techniques that are employed. As outlined in section B8 above, the degree of risk associated 
with these risks is either very low, and where possible, procedures will be implemented to 
further minimize any risks. 
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Stage 
Humphrey  
MD score 
Additional Criteria 
at least 1 of the listed criteria must apply) 
Stage 0: 
No or 
Minimal 
Defect 
  
Stage 1: 
Early 
Defect 
≥ -6.00 
dB 
- a cluster of ≥ 3 points on the pattern 
deviation plot in an expected location of the 
visual field depressed below the 5% level, at 
least one of which is depressed below the 
1%  level 
- CPSD/PSD significant at P<00.5 
- GHT Outside Normal Limits"" 
Stage 2: 
Moderate 
Defect 
≥ -6.00 to 
-12.00 dB 
- ≥ 25% but <50% of points on the attern 
deviation plot depressed below the 5% level, 
and ≥15% but <25% of points deprese below 
the 1% level 
- at least 1 point within the central 5° with 
sensitivity of <15 dB but no points in the 
central 5° with sensitivity of <0 dB 
- only 1 hemifield containing a point with 
sensitivity <15 dB within 5° of fixation 
Stage 3: 
Advanced 
Defect 
≥ -12.01 
to -20.00 
dB 
- ≥ 50% but <75% of points on pattern 
deviation plot depressed below the 5% level 
and ≥25% but <50% of points depressed 
below the 1% level 
- any point within the central 5° with 
sensitivity <0 dB 
- both hemifields containing a point(s) with 
sensitivity <15 dB within 5° of fixation 
Stage 4: 
Severe 
Defect 
≥ -20.00 
dB 
- ≥ 75% of points on pattern deviation plot 
depressed below the 5% level and ≥50% but 
<50% of points depressed below the 1% level 
- at least 50% of points within the central 5° 
with sensitivity <0 dB 
- both hemifields containing >50% of points 
with sensitivity <15 dB within 5° of fixation 
Stage 5: 
End-
Stage 
Disease 
 Unable to perform HVFA in worst eye due to 
central scotoma or worst eye VA 6/60 or 
worse due to POAG. Fellow eye may be at any 
stage 
PSD=Pattern Standard Deviation, POAG=Primary Open Angle 
Glaucoma 
Hodapp E, Parrish RK II, Anderson DR. Clinical decisions in glaucoma. 
St Louis: The CV Mosby Co; 1993. pp. 52–61. 
 
 
